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Part I
Introduction

Chapter 1
General introduction
adapted from
Smits BW, Smeitink JA, van Engelen BGM.
Mitochondriale ziekten; orgaanspecialisme-overstijgend denken gevraagd
Nederlands Tijdschrift voor Geneeskunde 2008;152:2275-2281
Smits BW, van der Sluijs BM, van Engelen BGM.
The astrologist’s posture: a useful clinical observation
Journal of Neurology Neurosurgery and Psychiatry 2011;82:164
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caSe rePorT
A 47-year-old woman was evaluated for a 30-year history of bilateral ptosis and exer-
cise intolerance. She also had complaints of hearing loss and was recently diagnosed 
with type II diabetes mellitus. Her family history was remarkable. She had four older 
brothers. Two brothers had died, supposedly from cerebral hemorrhage; both had 
ptosis and hearing loss. The third brother had hearing loss only. The fourth brother had 
a phenotype comparable to that of the patient. The patient’s mother also had diabetes 
and hearing loss and died at age 77.
Physical examination revealed a divergent strabismus with bilateral restricted gaze in 
all directions. There was a mild generalized decrease in muscle strength. Sensory func-
tions and coordination were normal.
Creatine kinase was normal, cerebrospinal fluid lactate was elevated (3200 μmol/l, 
normal < 1900). Electromyography revealed mild myopathic features. There was slight 
cerebellar atrophy on brain MRI. A skeletal muscle biopsy showed ragged red fibers and 
cytochrome-c-oxidase negative fibers (Figure 1). Mitochondrial complex I activity was 
moderately decreased. Genetic analysis revealed an m.03243A→G mutation in the skel-
etal muscle mitochondrial DNA (mtDNA). Based on the clinical features and results from 
the ancillary investigations, a diagnosis of chronic progressive external ophthalmoplegia 
(CPEO) was reached according to European Neuromuscular Centre criteria [1].
Most neuromuscular neurologists would not have much trouble reaching the diagnosis 
of CPEO in this particular patient. A bilateral, adult onset slowly progressive external 
ophthalmoplegia is highly suggestive of a mitochondrial disorder, which was readily 
confirmed by skeletal muscle histology and the detection of a known pathogenic mtDNA 
point mutation. Physicians in other specialties might however have reached alternative 
diagnoses in this particular patient, ranging from “mitochondrial encephalomyopathy”, 
“complex I deficiency”, “an m.03243A→G point mutation” to “MIDDS (maternally in-
herited diabetes-deafness syndrome)”. None of these diagnoses are wrong, as they all 
describe a key characteristic of the patient. Conversely, all are incomplete and do not 
consider the complex relation between phenotype and genotype that characterizes most 
mitochondrial disorders.
The complexity of mitochondrial medicine is probably best illustrated by the m.03243A→G 
point mutation. With a prevalence of 16-236 /100.000, it is the commonest patho-
genic mtDNA point mutation [2-5]. Originally described as the cause of MELAS, the 
m.03243A→G mutation was later found in patients with MIDDS, CPEO, Leigh syndrome, 
focal segmental glomerulosclerosis, sensorineural hearing loss, maternally inherited 
cardiomyopathy and myoclonic epilepsy with ragged red fibers (MERRF), as well as in a 
variety of overlap syndromes [6-8]. Conversely, the MELAS phenotype can be caused by 
10 additional mtDNA mutations scattered across five different genes [6].
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The complex relation between phenotype and genotype is only one of the features of mito-
chondrial disorders that make it difficult to conduct clinical research. Other difficulties are 
the low prevalence of each individual mitochondrial phenotype and the large variations in 
the rate of disease progression, even within a cohort of patients with a similar phenotype.
Because of the difficulties associated with clinical studies, most of the scientific research 
has focused on the organelle (function, pathophysiology and genetics) rather than on the 
patient (phenotype, disease impact and treatment). This is clearly illustrated by the fact that 
the search term “mitochond*” yields 210.433 hits in Pubmed, while only 6 studies met 
the entry criteria for a 2006 Cochrane review on the treatment of mitochondrial disorders 
(which concluded that there was no evidence supporting the use of any intervention in 
mitochondrial disorders) [9].
Another factor that contributed to the shift towards basic research is the fact that better 
understanding of the function of the organelle is the likely key to the development of a 
medical treatment. Indeed, basic and translational research have led to several therapeutic 
strategies, including l-arginine in stroke-like episodes associated with MELAS, co-enzyme 
Q10 in primary co-enzyme Q10 deficiency and bone marrow transplant or dialysis in 
mitochondrial neurogastrointestinal encephalopathy (MNGIE) [10-12].
However, these strategies are applicable to specific disorders only and do not benefit the 
broader range of mitochondrial disorders. Although studies in cell lines and animals show 
some promising new therapeutic strategies, a causative treatment which fully ameliorates 
all symptoms, or even a treatment that prevents further decline is not expected in the near 
future for most mitochondrial disorders [13]. Therapeutic options for most present-day 
patients are therefore limited to symptomatic management. Symptomatic management 
however requires detailed knowledge about the patients’ signs and symptoms, as well 
as their perception of the disease impact on daily life activities and social participation.
This thesis therefore focuses on signs, symptoms and impact of disease in one of the estab-
lished mitochondrial disorders, chronic progressive external ophthalmoplegia (cPeo). 
CPEO is very suitable for studying the disease impact in mitochondrial disorders, since it is 
a classical and readily recognizable mitochondrial phenotype, it is relatively common and 
it mainly affects adults. Moreover, CPEO is characterized by a large genetic heterogeneity, 
which allows for the identification of specific genotype-phenotype relations.
As most other medical specialties, mitochondrial medicine has its own basic principles 
and vocabulary. A short introduction to mitochondrial function and genetics is provided 
below in order to facilitate reading and understanding of this thesis.
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MITochonDrIal STrucTure, funcTIon anD geneTIcS
Mitochondria are sphere- or oval-shaped cellular organelles consisting of two membranes: 
a smooth outer membrane and an inner membrane, which is highly folded into cristae 
(Figure 2a). The space within the inner membrane is called the matrix, whereas the space 
between the inner and the outer membrane is called the intermembrane space.
The main function of the mitochondria is ATP production through oxidative phosphoryla-
tion. This process is catalyzed by four enzyme complexes (complex I-IV) of the respira-
tory chain located within the inner membrane. These complexes couple the transfer of 
electrons derived from glycolysis and fatty acid oxidation in the mitochondrial matrix 
to the transport of H+-ions across the inner membrane into the intermembrane space. 
The resulting H+-gradient serves as an energy source required for the transformation of 
ADP+phosphate into ATP by complex V (Figure 2d).
figure 1: Histologic and electromicroscopic sections of the quadriceps muscle biopsy
Adapted with permission from H. ter Laak
Quadriceps muscle tissue showing serial sections (a, B, and c) of ragged red fibers (RR) and 
COX-negative or COX-deficient fibers (see c). The electron microscopic image (D) shows a large 
mitochondrion with normal cristae at the left; arrows point to paracrystalline inclusions.
Images a, B, and c respectively depict activity of succinic dehydrogenase (SDH), myofibrillar ATPase 
(preincubation at pH 4.2) and COX. Bars represent 100 micron (a, B, and c) and 0.5 micron (D).
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The genetics of mitochondrial disorders has some distinctive features. Most importantly, 
mitochondria contain their own strand of DNA (mtDNA), a single circular strand of 16.569 
base pairs (Figure 2b), which is exclusively inherited from the mother [14]. It encodes 37 
genes: 13 for subunits of complexes I, III, IV and V, 2 for rRNAs and 22 for mitochondrial 
tRNAs (Figure 2c). Interestingly, the “language” of mtDNA is somewhat different from 
nuclear DNA. For instance, the codon AUA codes for isoleucine in nuclear DNA, but 
figure 2: The deleterious effects of the m.03243A→G mutation on the mitochondrial respiratory chain
a a classic representation of a mitochondrion, with a smooth outer membrane and a highly 
folded inner membrane. B the mitochondrial DNA, a circular 16569 base pair DNA fragment. The 
largest genes are noted in the circle. c a mitochondrial transfer DNA (tRNA), in this case the tRNA 
that facilitates the incorporation of the amino acid leucine in various proteins. The base pair on 
position 3243 contains a mutation (the substitution of an adenosine (A) nucleotide by a guanine 
(G) nucleotide). D oxidative phosphorylation: pyruvate and fatty acids are metabolized inside the 
mitochondrial matrix. Electrons (e-) from their metabolites are transferred across respiratory chain 
complexes I - IV, which are located inside the inner membrane. The resulting H+-gradient serves as an 
energy source for complex V, which coverts adenosine diphosphate (ADP) into adenosine triphosphate 
(ATP).
The red arrows and crosses represent the detrimental effects of the m.03243A→mutation. This 
mutation leads to impaired incorporation of leucine into complex I, III and IV, resulting in loss of 
function. Consequently, H+-transport across the inner membrane is decreased, which ultimately results 
in a decreased capacity of complex V to convert ADP into ATP.
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for methionine in mtDNA [15]. An explanation for this is provided by the endosymbiotic 
hypothesis, which states that mitochondria descend from aerobic bacteria that colonized 
primordial eukaryotic cells lacking the ability to metabolize oxygen [16].
Each mitochondrion contains several strands of mtDNA, while the number of mitochon-
dria in individual cells can vary considerably, ranging from a few to several hundreds 
[17]. In a single cell, mutated mtDNA often coexists with normal (wild type) mtDNA, a 
concept called heteroplasmy. Higher levels of heteroplasmy (i.e. more mutated mtDNA) 
are generally associated with more severe cellular dysfunction. However, the percentage 
of heteroplasmy at which cellular function is impaired depends on rate of the oxidative 
phosphoralytion and therefore differs between various organs.
Mutation in the mtDna can be divided into three categories:
1) point mutations in one of the 13 genes coding for a respiratory chain complex sub-
unit. This type of mutation often results in severely decreased activity of the complex 
involved and is commonly associated with a severe phenotype
2) point mutations in of the 22 genes coding for a tRNA (Figure 2c+d). These can result in 
single or multiple respiratory complex deficiencies
3) point mutations in one of the two mitochondrial rRNA genes (12s and 16s rRNA)
4) large scale rearrangements: duplications or deletions, often affecting several thousand 
base pairs
MtDNA point mutations are maternally inherited. Heteroplasmy levels however can vary 
considerably within one family, as can disease severity and phenotype [18]. For unknown 
reasons, deletions and duplications are mostly sporadic.
MtDNA codes for only a minority of the proteins involved in mitochondrial function. 
nuclear Dna encodes all other mitochondrial proteins. Consequently mitochondrial 
disorders can also result from nuclear DNA mutations. Most of these mutations affect 
genes coding for either respiratory complex subunits or for mtDNA maintenance proteins. 
Inheritance is Mendelian.
MITochonDrIal DISorDerS
With an estimated prevalence of 1:5000, mitochondrial disorders are the commonest 
group of inborn errors of metabolism [19;20]. Mitochondrial disorders however comprise 
a genetically and clinically heterogeneous group of diseases, with manifestations ranging 
from adult-onset single organ dysfunction to severe neonatal multi-system failure.
In patients with mitochondrial disorders several seemingly unrelated organs or tissues 
can be affected. For example, skeletal muscles and the retina are commonly affected in 
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mitochondrial disorders, whereas the skin and the lungs are not. As a rule of the thumb, 
the susceptibility of tissues and cells to mitochondrial dysfunction largely depends on 
two factors: both a high energy demand and a low mitotic activity make tissues prone 
to mitochondrial dysfunction [21]. The latter is explained by the fact that during mitosis, 
normal and mutated mtDNA copies are randomly distributed over the two daughter cells. 
If by chance a daughter cell receives only few mutated mtDNA copies, it is likely to 
survive whereas a daughter cell with a high percentage of mutated DNA is not. As a 
result, after several mitotic cycles, heteroplasmy decreases. This concept is called random 
segregation (Figure 3).
An overview of the organs most commonly affected in mitochondrial disorders is listed 
in Table 1 [22]. Patients with mitochondrial disorders often have more than one of these 
figure 3: Random segregation of mutant and wild-type mitochondria during mitosis and its effect on 
phenotypic expression
Clonal mtDNA
proliferation
Nucleus
*
Random
segregation
Disease phenotype Normal phenotype
Threshold for
phenotypic expressionWild-type mitochondria
Mutant mitochondria
Adapted with permission from Macmillan Publishers Ltd: Nature Review Genetics, copyright 2002.
Somatic mosaicism for mitochondrial disorders results from the random segregation of mutant and 
wild-type mitochondria during mitosis, which can result in daughter cells with different proportions 
of mitochondrial mutations. Somatic mosaicism in monozygotic twins (not shown) has also been 
observed. This could be due to intrauterine differences in the allocation of cells as a result of 
variations in the placental vascular supply, stochastic developmental events and other environmental 
influences [42].
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symptoms. There are also several classical mitochondrial phenotypes, characterized 
by a fixed combination of symptoms. Some of these phenotypes are associated with 
specific mtDNA mutations (Table 2) [22]. With an estimated prevalence of 1:40.000, 
chronic progressive external ophthalmoplegia (CPEO) is one of the commonest mitochon-
drial phenotypes in adulthood [23].
Table 1: Overview of common signs and symptoms in mitochondrial disorders revealing a broad 
variety of organs and tissues that are possibly affected
Central nervous system psychomotor retardation or regression
epilepsy
cerebellar ataxia
myoclonia
dystonia
hemiparesis
hemianopsia, cortical blindness
migraine
Peripheral nervous system external ophthalmoplegia
proximal or bulbar myopathy
exercise intolerance
axonal neuropathy
sensory neuronopathy
Ear, eye sensorineural hearing loss
pigmented retinopathy
optic atrophy
Hematopoiesis sideroblastic anemia
pancytopenia
Heart conduction block
cardiomyopathy
Endocrine system diabetes mellitus
growth retardation, growth hormone deficiency
hypoparathyroidism
Digestive tract pancreatic insufficiency
dysmotility, pseudo-obstruction
Kidney focal segmental glomerulosclerosis
Toni-Debré-Fanconi syndrome
Bartter-like syndrome
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cPeo
CPEO was first described by the ophthalmologist von Graefe in 1868 [24]. The main 
clinical features are bilateral slowly progressive ptosis and weakness of the muscles 
associated with ocular motility. Like in most mitochondrial disorders, there is a large 
phenotypical heterogeneity. Age at onset can vary from childhood to well into adult life. 
In addition to external ophthalmoplegia, involvement of other muscles groups (bulbar, 
limb girdle and heart) is common. Other common clinical features in CPEO patients are 
sensorineural hearing loss, pigmented retinopathy, axonal polyneuropathy, cerebellar 
ataxia and several non neurological features, such as a cardiac conduction block and 
endocrine disorders, mainly diabetes mellitus [25].
A specific combination of clinical features within the CPEO spectrum was described 
in 1958 by Kearns and Sayre [26]. This mitochondrial phenotype, now known as the 
Kearns Sayre syndrome (KSS), is characterized by external ophthalmoplegia, an early 
age of onset, the presence of a cardiac conduction block and pigmented retinopathy. 
Table 2: Overview of the commonest classical mitochondrial phenotypes and the associated gene 
mutations
Acronym /eponym Phenotype Common mutations
MELAS Myopathy, Encephalopathy, Lactate Acidosis 
and Stroke-like-episodes
m.03243A→G
Leigh syndrome psychomotor retardation, bilateral basal 
ganglia necrosis, lactate acidosis
m.08993T→C
LHON Leber Hereditary Optic Neuropathy m.11778G→A, 
m.03460G→A, m.14484T→C
MERRF Myoclonic Epilepsy and Ragged Red Fibers m.08344A→G
Kearns-Sayre syndrome early onset CPEO, retinitis pigmentosa, cardiac 
conduction block, cerebellar ataxia
mtDNA deletion
CPEO Chronic Progressive External Ophthalmoplegia mtDNA deletion
NARP Neuropathy, Ataxia and Retinitis Pigmentosa m.08993T→C
MIDDS Maternally Inherited Diabetes-Deafness 
Syndrome
m.03243A→G
Pearson syndrome pancytopenia, pancreatic insufficiency mtDNA deletion
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The exact definition underwent some changes over time, but is nowadays generally ac-
cepted as the combination of external ophthalmoplegia, pigmented retinopathy, an age 
of onset below 20 years, and at least one of the following symptoms: cardiac conduction 
block, cerebellar ataxia or elevated CSF protein content [27].
Progressive external ophthalmoplegia is also one of the main clinical features in two other 
mitochondrial phenotypes, SANDO (sensory atactic neuropathy, dysarthria and ophthal-
moplegia) and MNGIE (mitochondrial neurogastrointestinal encephalopathy). As the 
acronyms indicate, the other prominent clinical features in SANDO are a severe sensory 
neuronopathy and dysarthria, while gastrointestinal symptoms (recurrent nausea, vomiting 
or diarrhea) due to intestinal dysmotility, axonal neuropathy and leukencephalopathy are 
part of the MNGIE phenotype [28;29].
CPEO was the first mitochondrial disorder for which the genetic defect was identified. In 
1989, Moraes reported a 1.3 to 7.6 kb deletion in skeletal muscle mtDNA of 21 CPEO 
patients [30]. However, a single mtDNA deletion was also found in 11 KSS patients. 
Though the heteroplasmy levels and location of the deletion were later found to differ 
between KSS and CPEO, this does not fully account for the differences in age at onset, rate 
of progression and the distribution of organ involvement between the two disorders [31]. 
Consequently, there is ongoing debate about whether CPEO and KSS are distinct entities, 
or part of a continuous spectrum [32].
After the initial description of mtDNA deletions in CPEO, later studies revealed that one 
third to one half of all CPEO cases were not caused by a mtDNA deletion [30;33]. Since 
then, numerous other mutations have been identified (Table 3) [34]. Mutations in some of 
these genes are associated with a rather specific phenotype. For example, a large majority 
of SANDO cases is caused by mutations in the nuclear polymerase gamma 1 (POLG1) 
gene on chromosome 15q25 [35]. In contrast, MNGIE is mainly caused by mutations in 
the nuclear thymidine phosphorylase gene on chromosome 22q13.32-qter [36]. Despite 
these recent advances in the genetics of CPEO, there are still CPEO patients - albeit a 
minority - in whom no mutation can be identified.
The workup of a patient with suspected CPEO can be difficult. A muscle biopsy is often 
required for histological, biochemical and genetic analyses. A diagnostic algorithm is 
provided in the discussion of this thesis.
The differential diagnosis of CPEO is limited. Oculopharyngeal muscle dystrophy (OPMD) 
is an adult onset myopathy. Like in CPEO, clinical features include ptosis, myogenic dys-
phagia and limb girdle weakness. However, OPMD is mostly an autosomal dominantly 
inherited disorder and extra-muscular features are typically lacking. Moreover, extra-
ocular weakness is mild in OPMD, while it is an early and severe symptom in CPEO. As 
a result of preserved extra-ocular muscle function, OPMD patients can compensate their 
ptosis by combinating retroflexion of the neck with downward gaze. This is referred to 
as the astrologist’s posture. Since downward gaze is also often severely limited in CPEO,
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Table 3: Mitochondrial and nuclear DNA mutations associated with CPEO
locus gene confirmed
MtDna
Large scale Variable Multiple +
rearrangements
Transfer RNA m.00642T→C tRNA Phe -
point mutations m.03243A→G tRNA Leu (UUR) +
m.03243A→T tRNA Leu (UUR) -
m.03249G→A tRNA Leu (UUR) -
m.03250T→C tRNA Leu (UUR) -
m.03254C→T tRNA Leu (UUR) -
m.03255G→A tRNA Leu (UUR) -
m.04267A→G tRNA Ile -
m.04274T→C tRNA Ile -
m.04285T→C tRNA Ile -
m.04290T→C tRNA Ile -
m.04298G→A tRNA Ile +
m.04302A→G tRNA Ile -
m.04308G→A tRNA Ile -
m.04309G→A tRNA Ile -
m.05628T→C tRNA Ala -
m.05636T→C tRNA Ala -
m.05692T→C tRNA Asn -
m.05698G→A tRNA Asn -
m.05703G→A tRNA Asn +
m.07458G→A tRNA Ser (UCN) -
m.07506G→A tRNA Ser (UCN) -
m.08342G→A tRNA Lys -
m.12276G→A tRNA Ser (AGY) -
m.12283G→A tRNA Ser (AGY) -
m.12294G→A tRNA Leu (CUN) -
m.12311T→C tRNA Leu (CUN) -
m.12315G→A tRNA Leu (CUN) +
m.12316G→A tRNA Leu (CUN) -
m.14723T→C tRNA Glu -
Coding and control m.11232T→C MT-ND4 -
point mutations m.13094T→C MT-ND5 -
nuclear Dna 15q25 POLG1 +
17q23-q24 POLG2 +
10q24 Twinkle +
4q35 ANT1 +
3q28-q29 OPA1 +
22q13.32-qter TYMP +
8q23.1 RRM2B +
Adapted from www.mitomap.org
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CPEO patients rarely use the astrologist’s posture to compensate their ptosis (Figure 4) [37]. 
Myasthenia gravis is an acquired neuromuscular disorder characterized by external oph-
thalmoplegia and dysphagia. Again, extra-muscular features are lacking. One of the main 
features of myasthenia gravis is exercise induced augmentation of weakness. As a result, 
muscle weakness shows marked variations during the day and the extent of extra-ocular 
weakness is often asymmetric. In CPEO, marked asymmetry and predominant exercise 
induced weakness are uncommon. Congenital myasthenic syndromes (CM) comprise a 
group of hereditary disorders characterized by muscle weakness, mostly due to a mutation 
in the postsynaptic acetylcholine receptor. Weakness can affect the extra-ocular, bulbar, 
limb and respiratory muscles, depending on the subtype [38]. Differentiation between 
CM and CPEO can be particularly difficult, although there are some distinctive features:
1) CM patients often present in infancy or early childhood, while disease onset in CPEO 
is often in adulthood or adolescence
2) muscle weakness is often the sole feature of CM, while extra-muscular features are 
common in childhood onset CPEO
3) although muscle weakness can fluctuate in CPEO, prominent fluctuations are rare
4) a decrement of the compound motor action potential (CMAP) after repetitive nerve 
stimulation suggests CM
5) elevated venous lactate and ragged red fibers or COX-negative fibers in a skeletal 
muscle biopsy suggest CPEO
figure 4: The patient with oculopharyngeal muscular dystrophy (left) compensates his bilateral 
ptosis with the astrologist’s posture. Because of restricted downward gaze, the patient with chronic 
progressive external ophthalmoplegia (right) is unable to use this compensation.
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The prognosis in CPEO is highly variable. Although there are no controlled studies on 
age of death in CPEO, available data indicate that life expectancy for the whole group is 
decreased to about 50 to 60 years [23]. The rate of disease progression is more severe in 
patients with a disease onset below 9 years and in patients with central nervous system 
involvement, including retinal and cochlear dysfunction [25].
Only one therapy has a proven beneficial effect in CPEO. An aerobic cycle training sched-
ule was found to decrease fatigue and to increase physical endurance, daily physical ac-
tivities and leg muscle strength [39]. However, the 12 weeks, four times weekly schedule 
is demanding and therefore not suitable for patients with advanced disease. Tetracycline 
500 mg daily has been shown to delay progression of extra-ocular muscle weakness over 
a four year period in a single patient [40]. However, the effect of tetracycline has yet to 
be confirmed in a larger cohort. Last, a beneficial effect of nutritional supplements, most 
importantly co-enzyme Q10, has been reported in several uncontrolled trials [41].
ouTlIne of ThIS TheSIS
The aim of this thesis is to delineate the CPEO phenotype, in order to more fully appreciate 
the multi-organ involvement. This helps to indentify the specific symptoms and disabilities 
in the individual patient, which ultimately allows for optimal personalized symptomatic 
management.
Patients’ management generally starts with a diagnostic workup in order to reach the cor-
rect diagnosis. In Part II we provide several considerations for the workup of a suspected 
mitochondrial disorder: chapter 2 describes a study on the value of mitochondrial respira-
tory chain complex activities for the discrimination between mitochondrial disorders and 
the chronic fatigue syndrome, a condition of unknown etiology which can phenotypically 
resemble a mitochondrial disorder. chapter 3 describes the first case of CPEO caused by 
a specific point mutation in the mitochondrial isoleucine tRNA.
Part III provides a broad overview of the CPEO phenotype. This includes studies on the 
impact of disease (chapter 4), sleep disturbances (chapter 5), respiratory involvement 
(chapter 6) and on renal involvement (chapter 7).
All chapters are summarized in Part IV, which also contains a diagnostic algorithm, sug-
gestions for patient management and a section on future perspectives.
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aBSTracT
We studied the extent of mitochondrial involvement in chronic fatigue syndrome (CFS) 
and investigated whether measurement of mitochondrial respiratory chain complex (RCC) 
activities discriminates between CFS and mitochondrial disorders. Mitochondrial content 
was decreased in CFS compared to healthy controls, whereas RCC activities corrected for 
mitochondrial content were not. Conversely, mitochondrial content did not discriminate 
between CFS and two groups of mitochondrial disorders, whereas ATP production rate and 
complex I, III and IV activity did, all with higher activities in CFS. We conclude that the 
ATP production rate and RCC activities can reliably discriminate between mitochondrial 
disorders and CFS.
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InTroDucTIon
Patients with non-specific neuromuscular complaints, such as fatigue, myalgia and exer-
cise intolerance can pose a diagnostic dilemma. These complaints can either be the sole 
features of a mitochondrial disorder but can also occur in the absence of any recognizable 
somatic disorder [1]. In the latter case, the patient is often diagnosed with chronic fatigue 
syndrome (CFS) [2]. When in doubt between a mitochondrial disorder and CFS, a skeletal 
muscle biopsy can be performed for further differentiation [3].
Skeletal muscle is highly suitable for histological examination and is the tissue of choice 
for the measurement of the activities of the four mitochondrial respiratory chain complexes 
(RCC) involved in adenosine triphosphate (ATP) production. Decreased activity of one or 
more RCCs is suggestive of a mitochondrial disorder but is also reported in physically 
inactive, otherwise healthy subjects [4;5]. Since physical inactivity is common both in 
mitochondrial disorders and in CFS, the diagnostic value of measuring skeletal muscle 
RCC activities is unsure.
Here, we determined the diagnostic value of RCC activities for the discrimination between 
mitochondrial disorders and CFS. For this purpose, we first determined the extent of mi-
tochondrial involvement in CFS by comparing skeletal muscle biopsies of CFS patients 
to those of healthy controls. Next, to determine the diagnostic value of RCC activities 
we compared muscle biopsies between CFS patients and two groups of patients with 
genetically confirmed mitochondrial disorders.
MeThoDS
cfS patients
To determine the extent of mitochondrial involvement in CFS we compared RCC activities 
in skeletal muscle biopsies between CFS patients and healthy controls. The CFS group was 
recruited from patients who had undergone a muscle biopsy with measurement of RCC 
activity for evaluation of a suspected neuromuscular or mitochondrial disorder between 
2005 and 2007. All patients met the US Center for Disease Control (CDC) criteria for CFS 
[2;6;7]. According to these criteria patients have to be severely fatigued (operationalised 
as a score of ≥ 35 on the subscale fatigue of the Checklist Individual Strength) and the 
fatigue has to last longer than 6 months. The fatigue is neither the result of a somatic or 
psychiatric disease or of ongoing exertion, nor is it alleviated by rest. According to the 
CDC definition patients should also have four out of eight additional symptom criteria. 
These are myalgia, multi-joint pain, headaches, a sore throat, post-exertional malaise, 
unrefreshing sleep, concentration and/or memory impairments, and sensitive lymph 
nodes. The patients included in the present study should meet this criterion but at least 
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have myalgia and/or exercise intolerance. The CFS symptoms have to lead to substantial 
functional impairment, operationalised in the present study as having a score of 700 or 
higher on the Sickness Impact Profile (SIP8) [8;9].
All patients underwent a physical examination and laboratory tests to rule out an underly-
ing medical condition that could explain the symptoms. Therefore, all CFS patients had:
1. Normal physical and neurological examination, performed by a neurologist special-
ized in neuromuscular disorders
2. No family history suggestive of a neuromuscular or mitochondrial disorder
3. Normal routine blood tests (serum blood count, liver, renal and thyroid function, 
glucose, creatine kinase, lactate)
4. Normal muscle histology
5. No newly diagnosed medical condition explaining the fatigue during a follow up 
period of at least two years
controls
Healthy controls were recruited among medical students. None of these controls partici-
pated in professional or high intensity sports. Needle biopsies were taken from the right 
quadriceps muscle in all participants. All gave their written informed consent and the 
study was approved by local medical ethics committee.
Mitochondrial disorders
We compared the biopsies of CFS patients to those of two groups of mitochondrial dis-
orders. One group consisted of all patients (n=22, 11 female) with genetically confirmed 
chronic progressive external ophthalmoplegia (CPEO) diagnosed at the Neuromuscular 
Center Nijmegen (mtDNA deletion in 14 patients, mtDNA point mutation in three, mul-
tiple mtDNA deletions associated with homozygote or compound heterozygote nuclear 
polymerase gamma 1 mutation in five). The other group consisted of all patients (n= 27, 15 
female) registered at the Nijmegen Department of Human Genetics with an m.03243A→G 
mutation (A3243G) in skeletal muscle (mean heteroplasmy: 63.8%). All A3243G patients 
had phenotypes that were known to be associated with the m.03243A→G mutation. Two 
CPEO patients carrying the m.03243A→G mutation were included in the A3243G group 
only. All but three A3243G patients were previously described in detail, including correla-
tions between heteroplasmy levels and RCC activities [10]. 
Muscle biopsy handling
Muscle biopsies underwent routine histological staining for light microscopy. Fiber 
typing was performed according to a standard procedure of determining ATPase activ-
ity under different pH-conditions (pH 4.3, 4.6 and 10.3) [11]. ATP production rate and 
mitochondrial RCC activities (complex I, II+III, III and IV) were measured in fresh muscle 
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according to methods described previously [12]. In addition, we determined the activity 
of the mitochondrial matrix enzyme citrate synthase (CS; in mU/mg protein) as a marker 
for mitochondrial content in the muscle biopsy samples [13]. Since RCC activities are 
notably affected by the total mitochondrial content in the muscle biopsy, all RCC activi-
ties were normalized to CS activity. Consequently, ATP production rate is expressed in 
nmol ATP/h/mU CS and RCC activities in mU/U CS.
analysis
Mann-Whitney and Kruskal-Wallis tests were used to compare means, with p<0.05 (two-
sided) indicating significance. We constructed receiver operating characteristic (ROC) 
curves to compare RCC activities of the CFS patients to the RCC activities of the healthy 
controls and of the two groups of mitochondrial disorders. We calculated an area under 
the curve (AUC) for all ROC curves as a determinant of discriminative value [14]. In gen-
eral, an AUC of 0.5 indicates that the test has no discriminative value, whereas an AUC of 
1 indicates 100% discriminative power. Here, we considered a test to have discriminating 
value when the AUC was above 0.7.
reSulTS
Sixteen patients (9 female) met the criteria for CFS. Mean Checklist Individual Strength 
fatigue score was 52.8 (range 44-56), mean SIP8 score 1265 (range 720-2288) and mean 
CDC symptom inventory score 6.6 (range 4-9). Eleven male healthy controls were re-
cruited. Age at biopsy was 29.0 ± 10.8 years in controls, 38.3 ± 8.3 in CFS, 44.0 ± 10.1 in 
CPEO and 28.0 ± 16.1 in A3243G. The percentage of type I fibers did not differ between 
groups (controls 44%, CFS 44%, CPEO 43%, A3243G 49%, p=0.588). COX negative 
and ragged red fibers were only found in CPEO patients (23.4% and 3.4%) and in A3243 
(2.7% and 5.2%) patients. Histological biopsies of 9 A3243G patients were performed in 
another center and could not be traced.
Mitochondrial involvement in cfS
CS activity, a marker for mitochondrial content, was decreased in CFS patients compared 
to healthy controls (97 ± 32 vs. 180 ± 49 mU/mg protein, p<0.001) (Figure 1). There were 
no differences in RCC activities or ATP production rate.
Diagnostic value of rcc activities in cfS vs. mitochondrial disorders
Complex I, III and IV activity and ATP production rate discriminated (AUC > 0.7) between 
CFS patients and both groups of mitochondrial disorders, with lower enzyme activities in 
the mitochondrial disorders (Table 1, Figure 1). In contrast, CS activity had no discrimina-
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tive value, nor did complex II+III. The latter is in agreement with the fact that CPEO and 
A3243G patients usually have deficiencies in the RCCs that mainly consist of mtDNA 
encoded subunits rather than in the entirely nuclearly coded complex II subunits.
figure 1: Scatter plots of the activity of mitochondrial respiratory chain complexes I, II+III, III and IV, 
the ATP production rate and citrate synthase activity.
* area under the curve > 0.7 in comparison to CFS
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The highest discriminative values (i.e. highest AUCs) were found for complex IV activity 
and ATP production rate. However, at cut off values with 100% sensitivity for CFS (mean-
ing that no CFS patients are incorrectly diagnosed with a mitochondrial disorder), the 
specificity of the ATP production rate was much higher than the specificity of complex IV 
activity (Table 2).
In the four A3243G patients with the highest heteroplasmy levels (>87%), ATP production 
rate and RCC activities were below the cut off values in Table 2. In contrast, ATP produc-
tion rate and RCC activities were above the cut off values in all three A3243G patients 
with the lowest heteroplasmy levels (< 34%), as described before [10].
DIScuSSIon
Studying the extent of mitochondrial involvement in CFS, we found that mitochondrial 
function is unaffected in skeletal muscle of CFS patients whereas mitochondrial content 
Table 1: Areas under the receiver operating characteristic curves (AUC ROC) comparing the CFS 
patients to healthy controls and to CPEO and A3243G patients.
CFS vs.
Control
CFS vs.
CPEO
CFS vs.
A3243G
Complex I 0.52 (0.29-0.74) 0.78 (0.63-0.93) 0.82 (0.69-0.95)
Complex II+III 0.58 (0.36-0.80) 0.67 (0.49-0.85) 0.64 (0.47-0.81)
Complex III 0.52 (0.29-0.74) 0.85 (0.73-0.98) 0.83 (0.71-0.95)
Complex IV 0.66 (0.45-0.87) 0.91 (0.82-1.0) 0.88 (0.78-0.98)
ATP production 0.66 (0.42-0.90) 0.90 (0.79-1.0) 0.87 (0.76-0.98)
Citrate synthase 0.96 (0.0-1.0) 0.69 (0.51-0.86) 0.57 (0.39-0.74)
Tests with discriminative value (AUC > 0.7) are in bold.
Table 2: Cut off values with a 100% sensitivity for CFS and the associated specificities vs. CPEO and 
A3243G
cut off value with
100% sensitivity
for CFS
specificity for CFS 
vs. CPEO
(%)
specificity for CFS 
vs. A3243G
(%)
Complex I (mU/U CS) 60 48 67
Complex III (mU/U CS) 2153 50 52
Complex IV (mU/U CS) 1327 55 56
ATP production (nmol ATP/h/mU CS) 37.2 75 72
Complex II+III and citrate synthase activity did not have discriminative value and are therefore not 
included in this table.
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(indicated by CS activity) is notably decreased. Mitochondrial content has previously been 
related to the level of physical activity: mitochondrial content is low in physically inactive 
subjects and increases in response to training, both in otherwise healthy subjects as in 
patients with mitochondrial disorders [4;5;15;16]. This may suggest that low mitochon-
drial content in the present cohort of CFS patients is the consequence rather than the 
cause of physical inactivity. Nevertheless, regardless of cause or consequence, low mito-
chondrial content might be a perpetuating factor for complaints such as fatigue, myalgia 
and exercise intolerance in CFS, while an increase in mitochondrial content secondary 
to increased habitual physical activity can contribute to the beneficial effects of graded 
exercise treatment in CFS [17].
The present study is the first to directly compare mitochondrial function between pa-
tients with CFS and with mitochondrial disorders. However, there are previous studies 
comparing CFS patients to healthy controls, with conflicting results. Some studies found 
no differences between CFS and controls [18-21]. In contrast, others found evidence 
for mitochondrial dysfunction in CFS, consisting of a decreased anaerobic threshold to 
incremental exercise, or a decreased post exercise ATP recovery rate on skeletal muscle 
magnetic resonance spectroscopy [22-27]. However, incremental exercise tests or skeletal 
muscle magnetic resonance spectroscopy do not differentiate between decreased mito-
chondrial content and decreased mitochondrial function. Since the present results do not 
support the concept of primary mitochondrial dysfunction in CFS, we hypothesize that the 
findings of these previous studies might be attributed to decreased mitochondrial content.
We found that ATP production rate was the most reliable test to discriminate between 
CFS and mitochondrial disorders. ATP production rate was within the normal range in 
all CFS patients whereas it was decreased in grossly three quarters of the patients with 
mitochondrial disorders. Patients with an ATP production rate below the proposed cut off 
value can therefore reliably be diagnosed with a mitochondrial disorder, without the risk 
of incorrectly diagnosing CFS patients with a mitochondrial disorder. However, an ATP 
production rate above the proposed cut off value does not discriminate between CFS and 
mitochondrial disorders.
concluSIonS
The diagnosis of a mitochondrial disorder often relies on multiple laboratory diagnostic 
tests, such as mtDNA sequence analysis, metabolite profiling, and muscle histology. The 
present results however demonstrate that the ATP production rate and RCC activities can 
be used to discriminate between CFS and mitochondrial disorders in patients with non-
specific neuromuscular complaints.
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aBSTracT
We found a heteroplastic m.04267A→G mutation in the mitochondrial tRNAIle in 
a 52-year-old patient with a five year history of progressive external ophthalmoplegia 
and exercise induced muscle cramps. This specific mutation had been described only 
once before in a patient with deafness, cerebellar dysarthria, muscle ache, fatigue and 
mental slowing, but no signs of external ophthalmoplegia. The fact that we found the 
m.04267A→G mutation in a patient with CPEO, an established mitochondrial phenotype, 
provides additional evidence for its pathogenicity. Moreover, our findings support the 
approach of sequencing all relevant mitochondrial tRNA genes in cases of CPEO that are 
not due to large scale mtDNA rearrangements.
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Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial disease, which 
mainly affects extraocular muscles. The majority of CPEO patients have single deletions or 
point mutations in the mitochondrial DNA (mtDNA) [1;2]. Pathogenic point mutations are 
almost exclusively located in tRNA coding regions, the isoleucine tRNA (tRNAIle) coding 
region being one of the hotspots. Mutation in four loci of this tRNAIle hotspot have been 
associated with CPEO, while mutations in nine other loci can cause a variety of mitochon-
drial disorders, mainly hypertrophic cardiomyopathy [1]. The m.04267A→G mutation in 
the tRNAIle has been reported once in a patient with mitochondrial myopathy [3]. Here, 
we present a patient with an isolated CPEO caused by the m.04267A→G mutation in 
tRNAIle.
A 52-year-old male had a five year history of double vision for which he was treated 
with prism glasses. He reported muscle cramps after intensive exercise, without muscle 
weakness, dysphagia or dysarthria. Family history was unrevealing. His medical history in-
cluded surgery for a L5-S1 lumbar disc herniation and lactase deficiency, which was well 
under control with a lactose-free diet. On neurological examination, he had symmetrical 
ophthalmoparesis in all directions and bilateral ptosis. Both ptosis and ophthalmoparesis 
worsened after prolonged horizontal gaze. Further neurological examination was normal.
Electromyography (EMG), including single fiber EMG, showed evidence of generalized 
myopathy with normal nerve conductions and neuromuscular transmission. Brain MRI and 
echocardiography were normal. Serum lactate was normal and creatine kinase was mildly 
elevated (391 U/l, normal <200). Antibodies against skeletal muscle and acetylcholine re-
ceptor were undetectable. Needle biopsy of the quadriceps muscle revealed 10% ragged-
red fibers, 50% cytochrome c oxidase (COX) negative fibers and abnormal mitochondria in 
electron microscopy (size differences, compact circular cristae, and paracrystalline inclu-
sions) (Figure 1). Measured according to standard procedures, both complex I activity as 
well as complex III activity and ATP production rate from pyruvate were decreased (53, 58 
and 64% of lowest reference value, respectively) in fresh skeletal muscle [4]. Activities of 
complex II, IV and V were normal. Molecular analysis of skeletal muscle mtDNA excluded 
large-scale rearrangements. Sequencing of several tRNA genes previously reported to be 
associated with CPEO revealed a heteroplasmic A to G mutation at position 4267 in the 
tRNAIle with a heteroplasmy level of approximately 50% in muscle [1].
This is the second report of a mitochondrial disease caused by an m.04267A→G mutation 
in the mitochondrial tRNAIle and the first report of an association with CPEO. Previously, 
Taylor et al. found the m.04267A→G in a patient with deafness, cerebellar dysarthria, 
muscle ache, fatigue and mental slowing since the age of 30 [4]. The level of heteroplasmy 
in muscle tissue in Taylor’s patient was 88%, compared to 50% in our patient. It is tempt-
ing to speculate that the percentage of heteroplasmy of the m.04267A→G mutation in 
skeletal muscle correlates with the age of onset and the disease severity, although in 
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general, genotype-phenotype correlations in mitochondrial disorders caused by mtDNA 
mutations are not clear.
We can only speculate about the link between the tRNAIle mutation and the combined 
complex I and III deficiency. Since complex I and III both have a high isoleucine content, 
impaired incorporation of isoleucine due to the tRNAIle mutation could have altered their 
assembly, thereby resulting in loss of function [1].
In conclusion, this is the first report of an association between CPEO and the m.04267A→G 
mutation in the mitochondrial tRNAIle. Since CPEO is a typical mitochondrial phenotype, 
this study provides additional evidence for the pathogenicity of this mutation. Further-
more, our findings support the approach of sequencing all relevant mitochondrial tRNA 
genes in cases of CPEO that are not due to large scale mtDNA rearrangements.
figure 1: Quadriceps muscle sections showing ragged-red fibers (RR’s) in a (hematoxylin-phloxine 
stain) and c (succinic dehydrogenase stain), abnormal mitochondria in B (electron microscopy), 
and COX negative fibers in D (cytochrome oxidase stain). The square inset in B shows an extra 
magnification of a mitochondrion with paracrystalline inclusions. c and D represent serial sections with 
one COX negative ragged-red fiber, two COX negative non-ragged-red fibers, and a longitudinal cut 
muscle fiber partly devoid of COX activity. Bars represent 50 micron (a, c, and D) and 0.5 micron (B).
	  
mf: myofibril; mit: region with mitochondria
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aBSTracT
We determined the extent of disease impact in 28 patients with genetically confirmed 
chronic progressive external ophthalmoplegia (CPEO) and compared the outcomes to 
those of matched myotonic dystrophy type I (DM1) patients.
CPEO patients reported a high frequency of severe fatigue (67.9%), pain (96.2%), depres-
sion (32.1%) and dependency in daily life (46.4%). The frequency and extent of depression 
were significantly higher than in DM1 patients (32.1% vs. 7.1%, p=0.040; mean Beck’s 
depression inventory for primary care score 3.8 ± 3.5 vs. 1.3 ± 1.4, p=0.001), as were 
fatigue severity, pain intensity and extent of functional impairments.
CPEO patients with polymerase gamma 1 mutations reported more functional impair-
ments than those with mitochondrial DNA mutations. Disease impact was however not 
influenced by most clinical features. The present results help physicians to identify and to 
treat the factors that influence quality of life in CPEO patients and to provide symptomatic 
treatment where needed.
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InTroDucTIon
Chronic progressive external ophthalmoplegia (CPEO) is one of the most common mito-
chondrial disorders in adults [1]. The defining symptom is a slowly progressive extraocular 
muscle weakness. Multi-system involvement is however common, causing functional 
impairments secondary to dysfunction of (proximal) skeletal muscles, retina, cochlea, 
cerebrum, cerebellum and heart [2].
The frequency and nature of these impairments (body level) are well documented in 
previous studies, but their impact on daily life activities (individual level) or participation 
(society level) are unknown [3-6]. In our experience, there is often a discrepancy between 
the generally mild impairments and the severe limitations in activities and participation 
in CPEO patients. This discrepancy may lead to underestimation of disease impact by the 
treating physician, which in turn could result in inadequate symptomatic treatment at the 
level of activities and participation.
Here, we used a set of validated questionnaires to systematically determine disease impact 
on daily life activities and participation in a large cohort of CPEO patients from a single 
tertiary referral centre. In order to identify possible associations between disease impact 
and mutation type or clinical features we only included patients with a known causative 
mutation, and all participants underwent standardized neurological examinations. To 
estimate the clinical relevance of our results, we compared questionnaires outcomes of 
CPEO patients to those of matched myotonic dystrophy type I (DM1) patients. DM1 is suit-
able for comparison with CPEO since it is a relatively common neuromuscular disorder 
and therefore well known to many neurologists. Moreover, like CPEO, DM1 also affects 
muscle, eye, brain, and heart.
MeThoDS
Patients
All CPEO patients known in Department of Neurology of the Radboud University Nij-
megen Medical Centre were invited to participate. As there are no commonly accepted 
criteria for CPEO, we only included patients with both characteristic clinical features and 
a known causative mutation [2]. Consequently, all participants met the following three 
criteria:
(1) a phenotype including a slowly progressive bilateral external ophthalmoplegia,
(2) a proven pathogenic mutation or deletion in the mitochondrial DNA (mtDNA) or in 
the nuclear polymerase gamma 1 (POLG1), Twinkle or adenine nucleotide translocator 
1 (ANT1) genes,
(3) exclusion of an alternative diagnosis.
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These inclusion criteria also cover two more or less specific mitochondrial phenotypes 
with external ophthalmoplegia as a key symptom: the Kearns–Sayre syndrome (KSS: oph-
thalmoplegia, pigmented retinopathy, age of onset below 20 years, and at least one of the 
following symptoms: cardiac conduction block, cerebellar ataxia, elevated CSF protein 
content) and SANDO (Sensory Atactic Neuropathy, Dysarthria and Ophthalmoplegia) 
[7-9]. In the present study, we used the term CPEO to describe all patients meeting the 
inclusion criteria and the terms KSS and SANDO to describe the specific subtypes only.
Age and sex matched controls were selected from a previously published cohort of geneti-
cally confirmed, adult onset DM1 patients, all of whom attended normal education [10]. 
All participants gave informed consent. Local ethical committee approved this study and 
the patients’ consent was obtained according to the Declaration of Helsinki.
Questionnaires
We used a set of validated questionnaires to evaluate several important determinants of 
disease impact:
Fatigue severity
Experienced fatigue is defined as an overwhelming sense of tiredness, lack of energy and 
feeling of exhaustion. We used the Checklist Individual Strength (CIS) to determine the 
severity of experienced fatigue [11]. CIS is a 20-item questionnaire, which measures the 
severity of fatigue in four different sub items: fatigue severity (8 items, range 8–56), re-
duced concentration (5 items, 5–35), reduced activity (3 items, range 3–21), and reduced 
motivation (4 items, range 4–28). Each item was scored on a seven-point scale. A CIS 
fatigue score equal to or higher than 35 indicates severe fatigue [11;12].
Pain
Analgesic use and intensity and location of pain were assessed with the McGill’s Pain 
Questionnaire (MPQ) [13]. Pain intensity was scored on a 100 mm horizontal visual ana-
logue scale (VAS) and was divided in minimal, actual and maximal VAS scores. Patients 
could allocate pain to one or more of 32 predefined body areas.
Depression
Depression was rated according to the Beck’s Depression Inventory for Primary Care 
(BDI-PC) [14]. This is a 7 item self-report instrument composed of cognitive and affec-
tive symptoms. Each item is scored on a 4-point scale. Scores equal to or higher than 5 
indicate depression [14]. BDI-PC was preferred over the complete BDI to avoid an overlap 
between physical aspects of fatigue and the somatic symptoms of depression.
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Functional impairments and independency
Functional impairments were assessed with the Dutch version of the Sickness Impact Pro-
file (SIP-136) [15]. The 136 items are divided into 12 categories: sleep and rest, emotional 
behavior, body care and movement, household management, mobility, social interaction, 
ambulation, alertness and intellectual functioning, communication, work, recreation and 
pastimes, and eating. The SIP-136 has no validated cut off value, as healthy controls are 
by definition free of disease related functional impairments.
The level of independency was assessed with the modified Rankin scale (mRS), a 7-point 
observer rated scale. The mRS scores 0–2 indicate independency in daily life activities 
[16]. In all questionnaires, higher scores indicate more disability.
Statistical analysis
Data analysis was performed using SPSS (version 17.0) for Windows. An independent 
Mann–Whitney U-test was used to compare means and a Fisher’s exact test to compare 
frequencies. Correlations were calculated using a Spearman coefficient and odds ratios 
using a binary logistic regression. Significance level was set at p < 0.05 (two-tailed) in all 
cases.
reSulTS
Patients
We identified 30 patients meeting the inclusion criteria. All were invited to participate, 
two male patients (one with an m.12315G→A mutation and one with a mtDNA deletion) 
refused because of a lack of motivation. In general, their clinical features and disease se-
verity were in the same range as the participants. Of 28 participants (12 men, 16 women), 
16 patients had a single mtDNA deletion, 4 a pathogenic mtDNA point mutation and 
8 a POLG1 mutation (Table 1). POLG1 mutations included a homozygous A467T in six 
patients and compound heterozygous A467T and W748S mutations in two (patients 27 
and 28). None of the patients had Twinkle or ANT1 mutations. Mean disease duration was 
23.3 ± 10.6 years and mean age of onset was 23.6 ± 11.7 years. Three patients met the 
criteria for KSS and 7 for SANDO.
Questionnaires
Fatigue severity
Severe fatigue (CIS fatigue score ≥ 35) was the most frequent complaint, being reported 
by 19 patients (67.9%) with a mean CIS fatigue score for the whole group of 40.0 ± 12.6. 
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Demographic characteristics, clinical features, mutation type, and outcomes on all other 
questionnaires did not differ between patients with or without severe fatigue.
Table 1: Demographic, genetic and clinical data of 28 CPEO patients
no.
sex / age 
/ age at 
onset
mutation
cerebellar
ataxia
periph.
neurop. dysarthria
cognitive
impairm.
proximal
myopathy
retinal / 
cochlear 
involv.
other
1 F/41/32 deletion - - - - - -/+ HT
2 F/28/17 deletion - - - - + -/-
3 F/33/14 deletion - - - - - -/- M
4 M/30/8 deletion + - - + + +/+
5 F/49/25 deletion - - - - + -/-
6 F/57/34 deletion - - - - + -/- CM, E
7 M/51/25 deletion - - + - + -/-
8 M/43/14 deletion + - + + + +/+ CB
9 F/50/13 deletion - - - - + -/-
10 F/56/17 deletion - - - - - -/-
11 M/57/12 deletion - - + - + -/-
12 F/45/5 deletion - - - - - -/-
13 F/35/25 deletion - - - - - -/-
14 F/42/26 deletion - - - - + -/-
15 F/37/12 deletion + - + - + +/+
16 F/54/29 deletion + - + + + +/+ AF
17 M/55/30 m.05709T>C - - - - - -/- O, E, C
18 M/54/48 m.04267A>G - - - - + -/-
19 F/50/12 m.03243A>G + - + - + -/+ DM, M
20 M/49/12 m.03243A>G - + - + - -/+ DM
21 M/75/54 POLG1 - + + - + -/-
22 F/42/30 POLG1 + SAN + - + -/-
23 M/54/35 POLG1 + SAN + + + -/-
24 F/48/25 POLG1 + SAN + + + -/-
25 M/46/39 POLG1 + SAN + + + -/-
26 M/39/23 POLG1 + SAN + - + -/-
27 F/48/24 POLG1 + SAN + - + -/+
28 M/46/21 POLG1 + SAN + + - -/-
Age and age at onset in years
C, cataract; CB, cardiac conduction block; CM, cardiomyopathy; DM, diabetes mellitus; E, epilepsy; 
HT, hypothyroidism; M, migraine; O, otosclerosis; POLG1, polymerase gamma 1; SAN, sensory 
atactic neuropathy.
+ presence of symptom; – absence of symptom.
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Pain
CPEO patients mainly reported pain in the upper legs and head (Figure 1). Only one pa-
tient (3.6%) reported no pain (actual, minimal and maximal VAS scores = 0 mm). Twelve 
patients (42.9%) reported pain on waking up, of whom 5 had moderate to severe pain. Ten 
patients (28.6%) reported limitations in daily activities due to pain. Among the 27 patients 
with pain, sixteen (59.3%) used analgesics, mostly acetaminophen (13 patients, 48.1%), 
NSAIDs (7 patients, 25.9%) and opioids (2 patients, 7.4%). Patients using analgesics had 
higher CIS reduced concentration (21.1 ± 10.0 vs. 13.5 ± 8.3, p=0.036) and SIP sleep and 
rest scores (104.8 ± 64.1 vs. 47.6 ± 33.2, p=0.033) than patients without analgesic use, 
while there were no differences in pain severity.
figure 1. Distribution of pain in CPEO patients showing the percentage of patients with pain in 32 
predefined body areas
Depression
Depression (BDI-PC score ≥ 5) was found in 9 patients (32.1%) and mean BDI-PC score 
was 3.8 ± 3.5. Only 2 of the nine patients with a depression used antidepressants, together 
with 2 non-depressed patients. Depression was associated with various other determinants 
of disease impact: depressed patients had higher CIS reduced motivation (20.3 ± 4.6 vs. 
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14.5 ± 6.4, p=0.012), CIS reduced activity (16.7 ± 3.6 vs. 11.4 ± 6.1, p=0.030) and total 
CIS scores (101.2 ± 16.9 vs. 80.7 ± 26.1, p=0.049) compared to non-depressed patients. 
Moreover, depressed patients were less likely to be independent (mRS 2) in daily life 
activities (11% vs. 74%, p=0.004) and had more severe functional impairments (total SIP 
score 2993 ± 1380 vs. 1621 ± 1320, p=0.017). This difference in total SIP score mainly 
consisted of significantly higher subscores on emotional behavior (204.9 ± 149.8 vs. 74.0 
± 120.7, p=0.010), body care and movement (580.1 ± 428.7 vs. 267.2 ± 348.6, p=0.025), 
mobility (248.7 ± 158.4 vs. 81.6 ± 189.6, p=0.005), social interaction (463.6 ± 274.4 vs. 
209.7 ± 243.1, p=0.018), and ambulation (257.6 ± 110.9 vs. 124.9 ± 116.8, p=0.005).
Functional impairments and independence
Fifteen patients (53.6%) were independent in daily life activities (mRS ≤ 2), whereas 13 
(46.4%) were not (mRS >2). Patients who were independent in daily life activities had 
lower CIS reduced motivation (13.8 ± 5.3 vs. 19.2 ± 6.6, p=0.015), CIS reduced activity 
(10.5 ± 5.5 vs. 16.4 ± 5.1, p=0.011), and total CIS scores (75.4 ± 25.6 vs. 101.1 ± 16.8, 
p=0.009) compared to patients who were not independent. As expected, non-independent 
patients reported more severe functional impairments (total SIP score 2659 ± 1175 vs. 
1584 ± 1616, p=0.018), with significantly higher SIP subscores on body care and move-
ment (497.8 ± 392.9 vs. 255.1 ± 377.3, p=0.017), mobility (191.0 ± 164.2 vs. 87.1 ± 
210.3, p=0.043), social interaction (377.7 ± 235.9 vs. 216.5 ± 294, p=0.021), ambulation 
(237.6 ± 119.4 vs. 106.8 ± 107.3, p=0.004), and communication (239.2 ± 191.2 vs. 94.7 
± 113.5, p=0.032).
cPeo vs. DM1 patients
To estimate the clinical relevance of our findings, we compared questionnaire results of 
CPEO patients to those of age and sex matched DM1 patients. CPEO patients were more 
often depressed than DM1 patients (32.1% vs. 7.1%, p=0.040). In addition, CPEO patients 
had higher CIS fatigue, CIS reduced activity and VAS scores and more severe functional 
impairments, indicated by a higher total SIP score (Table 2). The higher total SIP score 
mainly consisted of significantly higher subscores on emotional behavior, household 
management, social interaction and eating. Except for CIS reduced concentration, scores 
on all other questionnaires were non-significantly higher in CPEO than in DM1 patients.
Influence of clinical features or mutation type on disease impact
Several clinical features were associated with an increased risk of depression (Table 3). 
In contrast, none of the clinical features was associated with severe fatigue or non-inde-
pendency in daily activities, though there was a strong tendency towards an association 
between non-independency and cerebellar ataxia, peripheral neuropathy and dysarthria. 
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Also, fatigue severity, depression, pain and level of independency were not influenced by 
sex, age or disease duration.
The SANDO phenotype was only present in patients with POLG1 mutations, while only 
one of the patients with POLG1 mutations had a clinical phenotype different from SANDO. 
Patients with POLG1 mutations had more functional impairments (i.e. a higher total SIP 
score), with higher SIP subscores on body care and movement, household management, 
social interaction, ambulation, and communication (Table 4). The percentage of patients 
being independent in daily activities did not differ between patients with POLG1 muta-
Table 2: Aspects of disease impact in patients with CPEO and DM1
CPEO
(n=28)
DM1
(n=28)
cIS
 Fatigue 40.0 ± 12.6 34.0 ± 10.5 p=0.035
 Concentration 17.9 ± 10.0 18.1 ± 6.2
 Motivation 16.4 ± 6.4 14.1 ± 6.2
 Activity 13.1 ± 5.9 9.8 ± 5.4 p=0.044
BDI-Pc 3.8 ± 3.5 1.3 ± 1.4 p=0.001
MPQ
 Actual VAS pain 22.5 ± 24.6 9.1 ± 12.1 p=0.028
 Minimal  VAS pain 12.0 ± 14.9 7.7 ± 15.4 p=0.045
 Maximal  VAS pain 63.3 ± 27.2 30.6 ± 33.8 p=0.001
SIP
 Sleep and rest 93.9 ± 78.6 68.2 ± 61.0
 Emotional behavior 116.1 ± 142.3 15.3 ± 29.9 p=0.001
 Body care and movement 367.8 ± 397.0 201.0 ± 184.4
 Household management 228.2 ± 180.4 124.0 ± 86.6 p=0.026
 Mobility 135.3 ± 194.2 48.8 ± 91.9
 Social interaction 291.3 ± 276.2 109.7 ± 155.4 p=0.002
 Ambulation 167.5 ± 129.3 146.8 ± 125.5
 Alertness 224.4 ± 216.9 137.5 ± 132.0
 Communication 161.8 ± 168.3 103.9 ± 121.7
 Work 160.0 ± 159.4 130.3 ± 144.9
 Recreation and pastimes 114.7 ± 95.7 85.9 ± 76.3
 Eating 22.8 ± 45.1 4.8 ± 19.2 p=0.022
 Total 2083 ± 1505 1176 ± 821 p=0.031
DM1, myotonic dystrophy type 1; CIS, Checklist Individual Strength; BDI-PC, Beck’s Depression 
Inventory for Primary Care; MPQ, McGill’s Pain Questionnaire; VAS, Visual Analogue Scale; SIP, 
Sickness Impact Profile.
Scores are expressed as mean ± SD.
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tions and patients with mitochondrial DNA mutations or deletions (mRS 0–2: 75% vs. 
35%, p=0.096). However, moderately severe disability (mRS = 4: unable to walk without 
assistance and unable to attend to own bodily needs without assistance) was more com-
mon in patients with POLG1 mutations (50.0% vs. 11.1%, p=0.032). Fatigue severity, 
depression and pain did not differ between patients with or without POLG1 mutations. 
However, depression was more common in patients with SANDO phenotype than in 
patients with non-SANDO phenotypes (71% vs. 19%, p=0.020).
DIScuSSIon
We showed that severe fatigue, depression, pain and functional impairments contribute 
to disease impact in CPEO patients. We also found that disease impact was related to the 
mutation type, as patients with POLG1 mutations had more severe functional impairments 
than patients with mtDNA mutations or deletions.
We demonstrated that severe fatigue, defined as an overwhelming sense of tiredness, 
lack of energy and feeling of exhaustion was present in the majority of CPEO patients. 
Moreover, we found that severe fatigue was more common in CPEO than in DM1 or 
in several other neuromuscular disorders [17]. The excessive fatigue reported by CPEO 
patients could in part be attributed to exercise intolerance, a key symptom in mitochon-
drial myopathies [18]. However, the CIS fatigue questionnaire which we used to rate 
fatigue severity covers multiple aspects of fatigue. CIS fatigue questionnaire scores were 
Table 3: Odds ratios indicating the relation between clinical features and three aspects of quality of 
life: fatigue, depression and functional impairments
Severe fatigue
(CIS fatigue ≥ 35)
Depression
(BDI-PC ≥ 5)
Non-independent 
(mRS>2)
Cerebellar ataxia 0.5 (0.1-2.3) 9.8 (1.5-63.8)* 4.4 (0.9-21.8)
Peripheral neuropathy 1.2 (0.2-6.2) 7.5 (1.3-44.1)* 4.7 (0.9-24.8)
Dysarthria 0.7 (0.1-3.5) 2.8 (0.5-14.4) 4.5 (0.9-22.1)
SANDO phenotype 0.5 (0.1-3.1) 10.6 (1.5-76.1)* 4.1 (0.6-26.1)
Cognitive impairment 0.7 (0.1-4.0) 6.7 (1.1-40.4)* 2.5 (0.5-13.5)
Proximal myopathy 1.4 (0.3-7.8) 4.7 (0.5-45.5) 3.7 (0.6-22.8)
Retinal involvement 1.5 (0.1-16.8) 2.4 (0.3-20.8) 4.2 (0.4-46.5)
Cochlear involvement 1.6 (0.3-10.2) 3.0 (0.5-16.7) 2.5 (0.5-13.5)
CIS, Checklist Individual Strength; BDI-PC, Beck’s Depression Inventory for Primary Care (BDI-PC); 
mRS, modified Rankin scale; SANDO, sensory atactic neuropathy, dysarthria, ophthalmoplegia.
Expressed as odds ratio (95% confidence interval).
* p < 0.05
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Table 4: Aspects of disease impact in CPEO patients with mtDNA mutations or deletions (non-POLG1) 
versus patients with POLG1 mutations (POLG1)
CPEO
Non-POLG1
(n=20)
CPEO
POLG1
(n=8)
Demographics
 Sex (M:F) 7 : 13 5 : 3
 Age 45.8 ± 9.3 49.8 ± 11.1
 Age at onset 20.5 ± 10.7 31.4 ± 11.1 p=0.041
 Disease duration 25.3 ± 11.4 18.4 ± 6.3
cIS
 Fatigue 40.7 ± 12.9 38.5 ± 12.4
 Concentration 18.1 ± 10.7 17.3 ± 8.3
 Motivation 15.1 ± 5.4 19.5 ± 7.9
 Activity 12.6 ± 6.0 14.4 ± 5.9
BDI-Pc 3.6 ± 3.7 4.5 ± 2.9
MPQ
 Actual VAS pain 25.3 ± 23.5 15.0 ± 27.5
 Minimal  VAS pain 12.8 ± 13.9 9.7 ± 18.6
 Maximal  VAS pain 65.6 ± 23.8 57.1 ± 36.3
SIP
 Sleep and rest 100.1 ± 82.1 78.6 ± 71.9
 Emotional behavior 120.1 ± 150.2 106.1 ± 129.1
 Body care and movement 204.3 ± 208.8 776.4 ± 471.7 p=0.001
 Household management 172.6 ± 138.6 367.1 ± 206.1 p=0.019
 Mobility 103.7 ± 195.4 214.4 ± 178.4
 Social interaction 206.6 ± 248.1 503.3 ± 235.0 p=0.003
 Ambulation 122.4 ± 98.9 280.5 ± 132.4 p=0.007
 Alertness 213.4 ± 229.1 251.9 ± 194.6
 Communication 113.0 ± 127.1 283.8 ± 203.8 p=0.032
 Work 158.9 ± 158.3 162.8 ± 173.3
 Recreation and pastimes 103.8 ± 100.2 142.0 ± 82.8
 Eating 16.6 ± 40.2 38.5 ± 55.4
 Total 1635 ± 1317 3205 ± 1421 p=0.011
Modified rankin scale 2.2 ± 1.0 3.3 ± 0.9 p=0.017
CIS, Checklist Individual Strength; BDI-PC, Beck’s Depression Inventory for Primary Care; MPQ, 
McGill’s Pain Questionnaire; mtDNA, mitochondrial DNA; POLG1, polymerase gamma 1; VAS, Visual 
Analogue Scale; SIP, Sickness Impact Profile.
Scores are expressed as mean ± SD
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uniformly high on all aspects and we therefore think that fatigue in CPEO is more than 
exercise intolerance alone.
The high frequency of depression in this study is consistent with previous reports on CPEO 
as well as with reports on other mitochondrial disorders [19-25]. It is however in contrast 
to other chronic neuromuscular disorders such as DM1, hereditary motor and sensor 
neuropathy type I and facioscapulohumoral dystrophy, which are not associated with an 
increased risk of depression [17]. This discrepancy between mitochondrial disorders and 
other neuromuscular disorders suggests a causative relation between mitochondrial dys-
function and an increased risk of depression. This concept is supported by the previously 
reported association between mood disorders and decreased cerebral metabolic activity 
[26-28]. The frontal lobes may play a particularly important role in the development of 
depression in mitochondrial disorders since they have an important function in mood 
regulation, carry a relatively high percentage of mutant mitochondrial DNA and have a 
relatively high metabolic demand [29-31].
Patients with POLG1 mutations had more functional impairments than patients with 
mtDNA point mutations or deletions, despite a (non-significantly) shorter disease duration. 
Since there were no differences in concentration, motivation, activity and depression, 
these aspects of disease impact cannot explain the increased functional impairments in 
patients with POLG1 mutations. POLG1 mutations were however strongly associated with 
a sensory atactic neuropathy, which is a debilitating syndrome and may therefore account 
for the increased functional impairments in patients with POLG1 mutations [32].
To estimate the clinical relevance of our results, we compared questionnaires outcomes 
of CPEO patients to those of matched DM1 patients. Although disease impact in DM1 is 
commonly considered to be profound, CPEO patients more frequently and more seriously 
suffered from depression, pain and functional impairments in several domains (emotional 
behavior, household management, social interaction, and eating), while fatigue severity 
and limitations in almost all other domains were at least equal to DM1 [33;34].
Literature on disease impact in CPEO is limited. The present results confirm and extend 
previous findings of limitations in health related physical and common role activities, and 
perception of impaired general health and vitality in CPEO patients [35]. However, in 
contrast to our results, this previous study found normal subjective perception of mental 
health and normal social activities, and a low frequency of depression. The discrepancy 
between the former and the present study might be explained by the fact that we used a 
more extensive set of validated questionnaires to evaluate a wider range of quality of life 
aspects.
This study has several methodological limitations. First, the cross sectional design makes it 
impossible to determine the direction of associations. A longitudinal study design should 
be performed to differentiate between causes and consequences. Second, although our 
study population is one of the largest ever published in a prospective clinical study on 
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genetically confirmed CPEO patients, sample size is still small for extensive statistical 
analysis. As a consequence, possible relations and correlations might not be detected. 
Since CPEO is a rare disorder, inclusion of more genetically confirmed patients is very dif-
ficult. Last, this is a single centre study from a tertiary referral clinic. Our study population 
might therefore not be representative for the total population of CPEO patients. However, 
since the prevalence of CPEO is low and the diagnosis of CPEO requires specialized 
techniques, nearly all CPEO patients in the Netherlands are referred to a tertiary referral 
clinic. Moreover, since this study has a high participation rate, we think that the study 
population is indeed representative.
In conclusion, CPEO causes a profound impact on social and daily life activities, which 
is indeed more than meets the eye. From our data we conclude that management of 
CPEO patients should include screening for the main aspects of disease impact: fatigue, 
depression, pain, and functional impairments. As there is no cure for CPEO, symptomatic 
treatment of these aspects may improve quality of life. For this purpose we suggest a 
multidimensional approach aimed at the specific needs of the individual patient. This ap-
proach may include rehabilitation and medication for the treatment of depression or pain.
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aBSTracT
Background: Chronic progressive external ophthalmoplegia (CPEO) is a relatively common 
mitochondrial disorder. In addition to extraocular muscle weakness, various other organs 
can typically be affected, including laryngeal and limb muscles, cerebrum, cerebellum, 
and peripheral nerves. Given this multi-organ involvement, patients are likely to be prone 
to sleep disturbances. Here, we determined the nature, prevalence, and determinants of 
sleep disturbances in CPEO.
Methods: We used validated questionnaires for various sleep disorders and possible deter-
minants such as mood and anxiety, and we performed ambulant polysomnography (PSG) 
in 20 patients with genetically confirmed CPEO.
Results: Three quarters of patients reported nocturnal sleep dysfunction. Thirty-five percent 
of patients fulfilled the criteria for restless legs syndrome, 30% had excessive daytime 
sleepiness and 70% significant periodic limb movements. PSG recordings revealed sev-
eral indicators of a disrupted sleep architecture. Obstructive sleep disordered breathing 
was present in only one patient. However, four patients had an increased central sleep 
apnea index, all of whom had a polymerase gamma 1 mutation and a SANDO phenotype 
(sensory atactic neuropathy, dysarthria, ophthalmoplegia). Physical examination and 
questionnaire outcomes were poor predictors of PSG results.
Conclusion: Several specific sleep disturbances are part of the phenotype of CPEO. Given 
that the disease is otherwise incurable, symptomatic treatment of sleep disturbances may 
be an important tool to improve quality of life. Therefore, patients with CPEO should be 
actively screened for sleep disorders, with a low threshold to perform PSG.
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InTroDucTIon
Chronic progressive external ophthalmoplegia (CPEO) is a relatively common mitochon-
drial disorder. In addition to extraocular muscle weakness, various other organs can 
typically be affected, including laryngeal and limb muscles, cerebrum, cerebellum, and 
peripheral nerves.
Given this multi-organ involvement, patients are likely to be prone to sleep disturbances. 
Sleep disturbances are important to recognize, because they can have a profound negative 
effect on quality of life, but are often treatable. As there are little therapeutic options in 
CPEO, recognizing and treating a coexisting sleep disorder could provide an important 
therapeutic option to improve quality of life.
We therefore performed a detailed study on sleep disturbances in one of the largest co-
horts of genetically confirmed CPEO patients.
PaTIenTS anD MeThoDS
All 26 patients registered in the Dutch CRAMP database with a diagnosis of CPEO ac-
cording to previously published criteria were invited to participate [1;2]. The study was 
approved by the local ethical committee. All participants gave written informed consent 
according to the Declaration of Helsinki.
Patients were physically examined and completed several questionnaires: the Pittsburgh 
Sleep Quality Index (PSQI), the Epworth Sleepiness Scale (ESS), the Checklist Individual 
Strength-fatigue (CIS-fatigue), and the Hospital Anxiety and Depression Scale (HADS). 
Restless legs syndrome (RLS) was diagnosed based on the presence of the four diagnostic 
criteria [3].
Polysomnography (PSG) was performed at the patients’ homes using an ambulatory 
Embla A10 Recorder (Embla Systems, Broomfield, CO, USA). We recorded a respiratory 
polygraphy, bilateral central and occipital electroencephalography (EEG), eye movements, 
and submental and tibial electromyography (EMG). Sleep was scored according to the 
Rechtschaffen and Kales criteria [4].
We used the Fisher’s exact test, the Mann–Whitney U test, and the Spearman’s rank cor-
relation coefficient for data analyses.
reSulTS
Twenty patients agreed to participate (Table 1). A majority of patients (75%) had subjec-
tive nocturnal sleep dysfunction (indicated by a PSQI >5). Six patients (30%) reported 
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excessive daytime sleepiness (ESS score >10) and 15 (75%) severe fatigue (CIS-fatigue 
score ≥35). Nine patients (45%) had symptoms of depression (HADS-depression >8) and 
5 (25%) increased anxiety scores (HADS anxiety >8).
There were several indicators of disrupted sleep architecture: sleep efficiency was de-
creased (<80%) in five patients (25%) and the duration of wake after sleep onset was 
high (74 ± 61 min) (Table 2). Other indicators for disturbed nocturnal sleep were a high 
percentage of stage 1 sleep (20 ± 8.5%) and an increased arousal index (24.8 ± 17.2/h).
Nine patients (45%) had an increased periodic limb movement (PLM)-index (>15/h), eight 
of whom also reported subjective nocturnal sleep dysfunction. However, when comparing 
patients with and without increased PLM-index, there were no differences in sleep efficiency 
(83.5 ± 9.5 vs. 87.6 ± 12.0, p = 0.24) or arousal index (28.4 ± 23.7 vs. 21.8 ± 9.5, p = 0.68).
Seven patients (35%) reported RLS, two patients with POLG1 mutations and five patients 
with mtDNA mutations or deletions (29% vs. 38%, p = 1.00). Four of the seven patients 
Table 1: Characteristics, mutation type and clinical features of 20 patients with CPEO
Sex / age 
/ age at 
onset
Mutation mRS Cerebell. 
ataxia
PNP Retinal / 
cochlear 
involv.
Prox. 
myop.
Dysart. Cogn.
impair.
Other
1 F/61/34 Deletion 3 – – -/- + – + CM, E
2 F/34/14 Deletion 2 – – -/- – – –
3 F/60/17 Deletion 1 – – -/- – – –
4 F/29/17 Deletion 2 – – -/- + – –
5 F/42/32 Deletion 2 – – -/+ – – – HT
6 M/39/11 Deletion 2 – + -/- – – –
7 M/53/25 Deletion 2 – + -/- + B –
8 M/44/14 Deletion 2 + – +/+ + B + CB, PM
9 F/54/12 m.03243A>G 4 + – +/+ + C, B – DM, RA, M
10 M/55/12 m.03243A>G 4 – + -/+ – – + DM
11 M/65/36 m.12315G>A 2 – – -/- – – –
12 M/56/30 m.05709T>C 2 – – -/- – – – O, E, CT
13 M/55/48 m.04267A>G 2 – – -/- + – –
14 M/47/21 POLG 4 + + +/+ – C, B +
15 M/23/4 POLG 4 + + +/- + C + MC, CB
16 F/30/13 POLG 4 – + -/- + – – MC
17 M/43/23 POLG 4 + + +/+ + C +
18 M/51/39 POLG 4 + + +/+ + C, B + IF
19 M/63/53 POLG 1 – – -/- – – –
20 F/50/24 POLG 4 + + -/+ + C,B –
PNP, polyneuropathy; CM, cardiomyopathy; CB, conduction block; PM, pacemaker; C, cerebellar 
dysarthria; B, bulbar dysarthria; DM, diabetes mellitus; E, epilepsy; RA, rheumatoid arthritis; M, 
migraine; MC, myoclonia; O, otosclerosis; C, cataract; HT, hyperthyroidism; IF, infertility.
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with RLS had an increased PLM-index, whereas three did not (p = 0.642). Patients with 
RLS had comparable sleep latency (11.1 ± 11.3 vs. 18.1 ± 13.2 min, p = 0.19) and PSQI 
score (8.3 ± 3.0 vs. 7.2 ± 3.9, p = 0.316) as patients without RLS.
Four patients (20%) had an increased central apnea index (>5/h), all with a moderately 
severe disability (mRS score of 4), cerebellar ataxia, severe polyneuropathy, dysarthria, 
and a POLG1 mutation. Patients with an increased central apnea index had decreased 
total sleep time (365 ± 15 vs. 445 ± 57 min, p = 0.014), sleep efficiency (75.2 ± 13.1% 
Table 2: Outcomes of sleep monitoring
Sleep architecture
 Total sleep time (min.) 429 ± 61 (320-535)
 Sleep latency (min.) 16 ± 13 (0-43)
 REM latency (min.) 146 ± 81 (2-327)
 WASO (min.) 74 ± 61 (8-235)
 Sleep efficiency (%) 86 ± 11 (60-98)
 Sleep efficiency < 80% 5 (25%)
 Sleep stages (%)
  S1 20 ± 8.5
  S2 34 ± 10.4
  SWS 25 ± 9.6
  REM 19 ± 6.4
 Sleep stage changes (/h) 12.1 ± 3.0 (7.7-17.5)
 Arousal index (/h) 24.8 ± 17.2 (5.0-88.2)
 Arousal index > 15/h 15 (75%)
limb movements
 PLM index (/h) 25.5 ± 30.5 (0-115.2)
 PLM index >15/h 9 (45%)
Sleep related breathing
 AH-index (/h) 9.8 ± 11.8 (0-47.2)
 AH-index > 15/h 4 (20%)
 Obstructive apnea index (/h) 1.2 ± 1.8 (0-7.0)
 Obstructive apnea index > 5/h 1 (5%)
 Central apnea index (/h) 5.0 ± 10.1 (0-36.1)
 Central apnea index > 5 /h 4 (20%)
 Desaturation index (/h) 4.2 ± 4.6 (0-13.2)
 Desaturation index > 10/h 4 (20%)
WASO, wake after sleep onset; SWS, slow wave sleep; PLM, periodic limb movement; AH-index, 
apnea-hypopnea index.
Values are expressed as mean ± SD (range) or number (percentage).
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vs. 88.4 ± 8.8%, p = 0.047), arousal index (13.6 ± 8.0 vs. 27.6 ± 17.9, p = 0.023), and 
percentage of Rapid Eye Movement (REM) sleep (12.2 ± 5.1% vs. 20.1 ± 5.9%, p = 0.033). 
Obstructive apneas were very rare. Only patient had a mildly increased obstructive apnea 
index of 7.0/h which coincided with a severely increased central apnea index (36.1/h).
Subjective nocturnal sleep dysfunction did not predict any of the PSG results, while ESS 
and CIS-fatigue scores did not correlate with arousal index, sleep efficiency, or total sleep 
time.
DIScuSSIon
Using validated questionnaires and ambulant polysomnography, we showed that various 
sleep disturbances are part of the CPEO phenotype. Most notably, three quarters of patients 
reported subjective nocturnal sleep dysfunction. In addition, 35% of patients fulfilled the 
diagnostic criteria for RLS, and 30% had excessive daytime sleepiness. In contrast to what 
could be expected in a neuromuscular disorder that commonly affects laryngeal muscles, 
sleep recordings showed that obstructive sleep apneas were rare in CPEO. However, in 
CPEO patients with POLG1 mutations and a SANDO phenotype (Sensory Atactic Neu-
ropathy, Dysarthria and Ophthalmoplegia), central apneas were common.
Nine patients had an increased PLM-index, associated with elevated PSQI scores in eight. 
This combination suggests the presence of clinically relevant periodic limb movement 
disorder (PLMD). The overall prevalence of PLMD in our cohort was therefore 40% and 
RLS was found in 35%. These prevalences are clearly increased compared to the healthy 
population, but are also higher than in patients with neurodegenerative disorders includ-
ing Parkinson’s disease [5].
The coexistence of RLS and CPEO was described recently in a single patient with a POLG1 
mutation [6]. In contrast to the conclusions of this article, our data suggests that RLS is 
a clinical feature of CPEO in general, rather than a specific feature of POLG1 mutations.
In conclusion, CPEO is commonly associated with a number of sleep disorders. Routine 
screening may be warranted, as treatment of sleep disturbances may be one of the few 
therapeutic options to increase quality of life in patients with CPEO. As both subjective 
complaints and physical examination were poor predictors of polysomnography results, 
there should be a low threshold to perform sleep recordings in patients with CPEO.
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aBSTracT
Chronic progressive external ophthalmoplegia (CPEO) is a relatively common mitochon-
drial disorder. Weakness of the extra-ocular, limb girdle and laryngeal muscles are estab-
lished clinical features. Respiratory muscle involvement however has never been studied 
systematically, even though respiratory complications are one of the main causes of death. 
We therefore determined the prevalence and nature of respiratory muscle involvement in 
23 patients with genetically confirmed CPEO. The main finding was decreased respiratory 
muscle strength, both expiratory (76.8% of predicted, p=0.002) and inspiratory (79.5% 
of predicted, p=0.004). Although the inspiratory vital capacity (92.5% of predicted, 
p=0.021) and the forced expiratory volume in 1 second (89.3% of predicted, p=0.002) 
were below predicted values, both were still within the normal range in the majority of 
patients. Expiratory weakness was associated with a decreased vital capacity (rho 0.502, 
p=0.015) and decreased peak expiratory flow (rho 0.422, p=0.045). Moreover, expira-
tory muscle strength was lower in patients with limb girdle weakness (62.6 ± 26.1% of 
predicted vs. 98.9 ± 22.5% in patients with normal limb girdle strength, p=0.003), but 
was not associated with other clinical features, subjective respiratory complaints, disease 
severity or disease duration. Since respiratory involvement in CPEO is associated with 
severe morbidity and mortality, the present data justify periodic assessment of respiratory 
functions in all CPEO patients.
Nature and frequency of respiratory involvement in chronic progressive external ophthalmoplegia 73
InTroDucTIon
Chronic progressive external ophthalmoplegia (CPEO) is one of the most common mito-
chondrial disorders in adults [1]. The characteristic clinical feature is a slowly progressive 
weakness of the extraocular muscles, resulting in ptosis and restriction of eye movements 
[2]. CPEO is however often a multi-system disorder, affecting limb girdle and laryngeal 
muscles, retina, cochlea, cerebrum, cerebellum or heart. The prevalence and nature of 
respiratory involvement has never been systematically studied.
Two cohort studies have shown that respiratory complications are one of the main causes 
of death in CPEO [3;4]. Conversely, studies that specifically investigated respiratory func-
tion in CPEO are limited to case reports and studies on small series of patients without 
a genetically confirmed diagnosis [5-10]. Most consistent findings were a decreased 
ventilatory drive to hypoxia and hypercapnia and respiratory muscle weakness. However, 
the prevalence, nature and determinants of respiratory involvement in CPEO cannot 
be reliably determined from these uncontrolled studies. More insight in the nature of 
respiratory involvement is nevertheless desirable, since it may help to prevent respiratory 
complications and respiration related deaths [4].
In a large cohort of genetically confirmed CPEO patients, we performed an extensive 
standardized assessment of respiratory muscle function, including spirometry, measure-
ment of respiratory muscle strength and of diffusion capacity. In order to identify possible 
determinants of respiratory muscle involvement, patients also completed questionnaires 
on subjective respiratory symptoms and underwent a standardized neurological examina-
tion.
MeThoDS
Patients
All CPEO patients known in the Department of Neurology of the Radboud University 
Nijmegen Medical Centre were invited to participate. As there are no commonly accepted 
criteria for CPEO, we only included patients with both characteristic clinical features 
and a known causative mutation. Consequently, all participants met the following three 
criteria:
1) a phenotype including a slowly progressive bilateral external ophthalmoplegia
2) a proven pathogenic mutation or deletion in the mitochondrial DNA (mtDNA) or in 
the nuclear polymerase gamma 1 (POLG1), Twinkle or adenine nucleotide transloca-
tor 1 (ANT1) genes
3) exclusion of an alternative diagnosis
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These inclusion criteria also cover two more or less specific mitochondrial phenotypes 
with external ophthalmoplegia as a key symptom: the Kearns-Sayre syndrome (KSS: ex-
ternal ophthalmoplegia, pigmented retinopathy, age of onset below 20 years, and at least 
one of the following symptoms: cardiac conduction block, cerebellar ataxia, elevated 
CSF protein content) and SANDO (Sensory Atactic Neuropathy, Dysarthria and Ophthal-
moplegia) [11-13]. In this article, we use the term CPEO to describe all patients meeting 
the inclusion criteria and the terms KSS and SANDO to describe the specific phenotypes 
only.
All participants gave informed consent. Local ethical committee approved this study and 
the patients’ consent was obtained according to the Declaration of Helsinki.
Patients’ characteristics
We performed a standardized neurological examination, including an assessment of 
muscle strength (ocular, bulbar and extremities), sensory functions, tendon reflexes and 
coordination. We also measured length and weight and calculated body mass index. 
Results of ancillary investigations and of genetic investigations were derived from the 
patients’ files.
Subjective complaints
All participants completed a questionnaire with items on history of smoking and pulmo-
nary disease, dyspnea, swallowing, coughing, and quality of sleep. We assessed the level 
of independency in daily activities using the modified Rankin score (mRS), with an mRS ≤ 
2 indicating independency [14].
Pulmonary function tests
All eligible patients were invited to undergo respiratory function tests in our pulmonary 
function department. To exclude a possible selection bias (patients who were unable to 
visit our hospital might have more advanced disease), we offered to perform respiratory 
function tests at home to those patients who were willing to participate but could not visit 
our hospital.
Respiratory function tests were performed according the American Thoracic Society / Eu-
ropean Respiratory Society standards [15]. First, we measured respiratory muscle strength, 
including the maximal expiratory mouth pressure (PE-Max), and the maximal inspiratory 
mouth pressure (PI-Max). Next, to evaluate the effect of respiratory muscle weakness on 
the inspiratory vital capacity (IVC) we performed spirometry, including the forced expira-
tory volume in 1 second (FEV1), the FEV1/IVC ratio, the peak expiratory flow (PEF) and the 
forced inspiratory volume in 1 second (FIV1). We also measured the total lung capacity 
(TLC), the diffusion capacity for carbon monoxide (TLCO) and the diffusion capacity for 
carbon monoxide corrected for alveolar volume (KCO).
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All tests were performed by a trained pulmonary function technician. The TLC, FIV1, TLCO 
and KCO could not be measured at the patients’ homes and were therefore measured in 
patients visiting our hospital only.
Statistical analysis
Data analysis was performed using SPSS (version 17.0). To assess the extent of pulmonary 
involvement in CPEO we compared the test results of the individual participants to their 
own predicted values using a paired Wilcoxon signed rank test. For comparison between 
various subgroups, we performed an independent Mann-Whitney U-test on the test results 
relative to the predicted values, which are noted as “value % pred”: for example, “IVC” 
indicates the inspiratory vital capacity (in liters), whereas “IVC% pred” indicates the in-
spiratory vital capacity relative to the predicted value (in %). A Fisher’s exact test was used 
to compare frequencies and a Spearman coefficient to calculate correlations. Significance 
level was set at p<0.05 (two-tailed) in all cases.
reSulTS
Patients’ characteristics
We identified 26 eligible patients. All were invited to participate, two patients refused 
(one male patient with an m.12315G→A mutation and one female patient with a mtDNA 
deletion). In general, their clinical features and disease severity were in the same range as 
the participants. During the tests, one of the participants appeared to be unable to follow 
the instructions due to severe vision and hearing impairments. Her test results were unreli-
able and therefore excluded from all analyses. Of the remaining 23 patients (11 female, 
12 male), 14 patients (60.9%) were tested in the pulmonary function department and nine 
(39.1%) at home. Mean age of the participants was 49.1 ± 11.0 years and mean age at on-
set was 22.9 ± 12.2 years (Table 1). Mutation type included a single mtDNA deletion in 14 
patients (60.9%), a mtDNA point mutation in four (17.4%) and a POLG1 mutation in five 
(21.7%). POLG1 mutations included compound heterozygous T251I, P587L and A957S 
mutations in one patient (patient 19), a homozygous A467T in two patients (patients 20 
and 21) and compound heterozygous A467T and W748S mutations in two (patients 22 
and 23). Three patients (19, 20 and 23) also had multiple mtDNA deletions in their skeletal 
muscle mtDNA. None of the patients had Twinkle or ANT1 mutations. Three patients (two 
with a mtDNA deletion and one with an m.03243A→G point mutation) met the criteria 
for KSS and four (all with POLG1 mutations) for SANDO. Fifteen patients (65.2%) were 
independent in daily life activities, whereas eight (34.7%) were not.
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Questionnaires
Five patients (21.7%) were current smokers and six of the remaining 18 patients (33.3%) 
were former smokers (Table 1). Three patients reported a history of asthma, of whom only 
one used pulmonary medication (budesonide). Three patients (13.0%) had a history of 
pneumonia, including two out of the three patients with asthma. Shortly after participating 
in this study, one additional patient (no. 3) developed a severe pneumonia, requiring me-
chanical ventilation and long term rehabilitation. We included this patient in the further 
analyses on patients with a history of pneumonia. Fourteen patients (60.9%) reported 
exertional dyspnea. Three patients (13.0%), two current smokers and one patient with 
Table 1: Demographical, genetic and clinical results of 23 CPEO patients
no.
sex / age 
/ age at 
onset
mutation
smoking
history
pulmon.
history
CNS 
involv.
limb 
girdle
periph.
neurop.
dysarthria / 
dysphagia other
1 F/28/21 deletion C - - - - -/-
2 F/43/32 deletion - - - - - -/- PHL, HT
3 F/29/17 deletion C P - + - -/+
4 F/35/14 deletion - - M - - -/-
5 M/32/8 deletion - - CA, CI + - -/+ PHL, RI
6 F/52/25 deletion - - - + - -/-
7 F/62/34 deletion F - CA, CI, E + - -/- CM
8 F/43/15 deletion C - - + - +/+
9 M/54/25 deletion F - - + - +/+
10 M/40/11 deletion C - - - - -/-
11 M/45/14 deletion F - CA, CI + - +/+ CB, PHL, RI
12 F/54/13 deletion F - - + - -/-
13 F/61/17 deletion F - - - - -/-
14 M/63/12 deletion - P - + - +/+
15 M/55/48 m.4267A>G - - - + - -/-
16 M/66/36 m.12315G>A - - - - - -/-
17 F/54/12 m.3243A>G F A, P CA, M + - +/- PHL, RI, DM
18 M/57/12 m.3243A>G C A CI - + -/- PHL, DM
19 M/63/53 POLG1 - - - - + -/-
20 M/52/39 POLG1 - - CA, CI + SAN +/- PHL, RI
21 M/43/23 POLG1 - - CA, CI + SAN +/+ PHL, RI
22 F/51/24 POLG1 - A, P CA + SAN +/+ PHL
23 M/48/21 POLG1 - - CA, CI - SAN +/+ PHL, RI
CNS, central nervous system; POLG1, polymerase gamma 1; C, current smoker; F, former smoker; 
P, pneumonia; A, asthma; M, migraine; CA, cerebellar ataxia; CI, cognitive impairment; E, epilepsy; 
SAN, sensory atactic neuropathy; CM, cardiomyopathy; CB, cardiac conduction block; PHL, 
peripheral hearing loss; RI, retinal involvement; DM, diabetes mellitus; HT, hypothyroidism
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asthma, reported dyspnea in rest. Eleven patients (47.8%) reported dysphagia, of whom 
three (13.0%) also reported difficulty coughing.
Pulmonary function tests
The main finding was decreased expiratory and inspiratory muscle strength: PE-Max was 
76.8% of the predicted value (p=0.002) and PI-Max 79.5% (p=0.004) (Table 2). Lower 
PE-Max% pred was associated with lower PI-Max% pred (rho 0.625, p=0.001) but also 
with lower IVC% pred (rho 0.502, p=0.015) and lower PEF% pred (rho 0.422, p=0.045). 
IVC was also significantly decreased (92.5% of predicted, p=0.021), as were FEV1 (89.3% 
of predicted, p=0.003) and TLCO (81.9% of predicted, p=0.002). The decreased TLCO is 
unlikely due to intrinsic lung disease, since the diffusion capacity corrected for alveolar 
volume (i.e. the KCO) was normal (97.9% of predicted, p=0.26). Three patients had ob-
structive pulmonary disease (FEV1/IVC < 70%), of whom two were former smokers and 
one a non-smoker without a history of pulmonary disease. In these three patients, all other 
test results were within the range as the rest of the cohort.
Determinants of respiratory function
Patients with limb girdle weakness had a lower PE-Max% pred than patients with normal 
limb girdle strength (62.6 ± 26.1% vs. 98.9 ± 22.5%, p=0.005). Limb girdle weakness 
was not associated with any of the other outcomes. PEF% pred was lower in patients 
who reported difficulty coughing (74.3 ± 9.5% vs. 98.8 ±18.1%, p=0.028), as well as in 
patients with a history of pneumonia (76.6 ± 9.0% vs. 99.7 vs. 18.3%, p=0.019). None 
of the other subjective complaints, demographic or clinical features were associated with 
any of the respiratory test results.
As to a possible genotype-phenotype relation, there were no differences in any of the 
respiratory test results between patients with mtDNA mutations or deletions and patients 
with POLG1 mutations, though there was a strong tendency toward a lower PE-Max% pred 
in patients with mtDNA deletions (66.4 ± 31.0% vs. 100.5 ± 26.0%, p=0.064). In addition, 
all eight patients with a PE-Max below 65% of the predicted value had a mtDNA deletion.
DIScuSSIon
We found that both expiratory and inspiratory muscle strength was decreased in CPEO 
patients and that decreased respiratory muscle strength resulted in a decreased vital 
capacity, FEV1 and PEF. Respiratory muscle weakness was associated with limb girdle 
weakness, which is in concordance with studies in other myopathies [16;17]. In contrast, 
there was no association between respiratory muscle function and other clinical features, 
disease duration, disease severity, subjective respiratory complaints, or mutation type.
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Table 2: Results of respiratory function assessment
no. BMI PE-Max PI-Max IVC TLC FEV1 FEV1/
IVC
PEF FIV1 TLCO KCO
1 24.7 9.4 (101) 8.0 (109) 3.8 (100) 4.7 (91) 3.3 (101) 87 9.0 (125) 3.3 (94) 8.9 (94) 2.0 (109)
2 34.7 11.6 (118) 8.3 (104) 4.7 (121) 6.2 (108) 3.7 (115) 80 8.0 (110) 4.5 (128) 8.2 (86) 1.4 (87)
3 16.8 4.0 (45) 5.1 (74) 2.1 (61) 4.3 (89) 2.0 (68) 95 5.2 (76) 2.0 (60) 6.9 (77) 1.8 (94)
4 23.5 9.5 (95) 6.6 (79) 3.8 (90) 5.1 (83) 3.3 (92) 87 8.0 (103) 3.7 (93) 7.0 (68) 1.6 (94)
5 17.9 7.7 (52) 7.2 (67) 4.0 (92) 4.9 (84) 3.1 (87) 78 7.8 (89) 3.8 (94) 7.2 (73) 1.5 (90)
6 34.4 4.3 (46) 5.4 (73) 2.5 (77) 2.1 (79) 85 5.6 (85)
7 30.0 7.3 (74) 5.4 (66) 3.9 (111) 6.9 (116) 2.6 (87) 67 8.3 (121) 3.8 (118) 7.8 (89) 1.3 (86)
8 19.0 2.8 (30) 3.7 (50) 2.9 (84) 4.5 (86) 2.6 (90) 95 6.2 (91) 2.4 (77) 6.5 (74) 1.6 (95)
9 27.8 2.4 (19) 1.7 (20) 4.4 (86) 3.5 (91) 81 6.8 (74)
10 27.3 10.7 (75) 4.4 (44) 4.8 (82) 6.1 (75) 3.7 (81) 77 10.0 (99) 4.3 (81) 10.0 (80) 1.7 (112)
11 18.9 6.9 (51) 10.2 (109) 4.8 (100) 3.8 (103) 81 9.0 (100)
12 21.8 5.1 (52) 5.0 (63) 3.7 (105) 5.3 (94) 2.9 (98) 77 6.8 (100) 3.6 (113) 7.3 (74) 1.5 (97)
13 30.1 10.6 (116) 8.0 (112) 3.2 (109) 4.4 (89) 2.3 (97) 78 7.1 (117) 2.9 (112) 5.6 (73) 1.4 (89)
14 25.9 7.2 (60) 2.7 (35) 3.7 (79) 2.7 (76) 72 5.5 (64)
15 25.3 12.7 (99) 8.2 (97) 5.1 (120) 6.8 (103) 4.5 (135) 87 11.9 (142) 5.0 (130) 9.5 (101) 1.5 (104)
16 24.2 10.1 (86) 5.0 (68) 2.8 (80) 2.3 (84) 80 7.6 (103)
17 23.0 7.7 (80) 8.1 (105) 3.8 (109) 5.3 (95) 2.3 (80) 61 5.6 (83) 3.4 (111) 7.6 (79) 1.5 (97)
18 16.9 8.4 (66) 8.2 (99) 3.5 (72) 2.6 (70) 75 6.2 (70)
19 29.1 16.5 (138) 8.2 (110) 3.7 (92) 6.4 (97) 2.1 (68) 56 5.9 (75) 3.5 (98) 9.4 (107) 1.8 (132)
20 24.4 9.0 (69) 8.0 (91) 3.6 (81) 2.8 (81) 80 8.1 (94)
21 18.0 12.3 (89) 6.4 (67) 5.3 (94) 7.9 (99) 4.1 (94) 78 9.7 (99) 5.1 (98) 8.6 (71) 1.3 (83)
22 21.5 10.7 (111) 8.9 (116) 3.5 (101) 2.6 (90) 74 5.6 (83)
23 27.2 12.7 (95) 6.6 (73) 4.4 (82) 3.6 (87) 82 9.1 (95)
mean 8.68 6.49 3.82 5.63 2.97 79 7.52 3.66 7.89 1.56
SD 3.49 2.13 0.80 1.11 0.70 9.2 1.73 0.88 1.27 0.20
%pred. 76.8** 79.5** 92.5* 93.6 89.3** 99.5 95.6 100.5 81.9** 97.9
In value (percentage of predicted)
BMI, body mass index (in kg/m2); PE-Max, maximal expiratory mouth pressure (in kPa); PI-Max, 
maximal inspiratory mouth pressure (in kPa); IVC, inspiratory vital capacity (in litres); TLC, total lung 
capacity (in litres); FEV1, forced expiratory volume in 1 second (in litres); PEF, peak expiratory flow (in 
litres/sec); FIV1, forced inspiratory volume in 1 second (in litres); TLCO, diffusion capacity for carbon 
monoxide (in mmol/min/kPa); KCO, diffusion capacity for carbon monoxide corrected for alveolar 
volume (mmol/min/kPa/litre)
Blank fields indicate that the patient was tested at home and as a result the specific test was not 
performed
* paired Wilcoxon p< 0.05
** paired Wilcoxon p< 0.01
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In the present study, we took several measures to include a representative cohort: our 
study was prospective and used strict clinical and genetic inclusion criteria. We also of-
fered to perform the tests at the patients’ homes, which resulted in a high participation 
rate. This not only enabled us to provide a representative overview of the prevalence and 
nature of respiratory involvement in CPEO, but also to identify possible determinants of 
respiratory involvement. The present results therefore not only confirm but also extend the 
conclusions of the previous smaller case studies on respiratory involvement in CPEO [5; 
6;9].
A major consequence of decreased respiratory muscle weakness in neuromuscular disor-
ders is an increased risk of pneumonia [18]. CPEO patients may however be particularly 
prone to pneumonias because of concurrent laryngeal muscle weakness. Laryngeal muscle 
weakness can lead to aspiration of foods and to diminish glottic closure during coughing 
[4;19;20]. Inadequate glottic closure in turn, especially when combined with decreased 
inspiratory and expiratory strength, results in insufficient generation of intrathoracic pres-
sure and thus in impaired expectoration.
In addition to an increased risk of pneumonia in CPEO, the course of pneumonia may 
theoretically also be more severe: a decreased ventilatory drive to hypoxia or hypercapnia 
predisposes to respiratory failure and prolonged weaning after mechanical ventilation 
[5;6;10]. In addition, CPEO patients may have trouble meeting the increased demands 
associated with infections because of limited metabolic and hemodynamic reserves [21].
Despite the fact that pneumonia is one of the main causes of death in CPEO, little is 
known about its prevention [3;4]. As in other neuromuscular disorders, conservative 
treatment aimed at minimizing the risk of pneumonia seems rational [22]. This includes 
speech therapy and physiotherapy aimed at optimizing cough effectiveness and swallow-
ing function, while a cricopharyngeal myotomy may be performed in selected cases of 
severe dysphagia [19]. Moreover, any sign of pneumonia or respiratory failure in a CPEO 
patient should prompt rapid diagnosis and treatment to prevent further complications.
The present study does not quantify the relative contributions of neurogenic or myogenic 
weakness of the respiratory muscles, nor the relative contribution of the various muscles 
involved in respiration. For instance we did not directly measure diaphragm strength, 
which ideally requires transdiaphragmic oesophageal and gastric manometry. This is 
however an invasive procedure and carries a risk of aspiration. Alternative indicators for 
diaphragm strength are the nasal sniff pressure and the supine vital capacity. The use 
of supine vital capacity is however limited by the lack of normal values. Sniff pressure 
is mainly validated in amyotrophic lateral sclerosis and depends partly on the nasal 
airway conductance, while in patients with myopathies, PI-Max is possibly a more reli-
able indicator of inspiratory weakness than nasal pressure [23]. Therefore in this study, 
we used the PI-Max as an indicator of diaphragm strength, since it is also correlated to 
transdiaphragmic pressure [24].
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concluSIonS
Respiratory muscle weakness is common in CPEO patients. The presence of respiratory 
muscle weakness has important consequences for patient management, since it is associ-
ated with an increased risk of pneumonia and possibly of increased mortality. As there 
are no clinical predictors of respiratory muscle weakness and the rate of progression of 
respiratory muscle weakness has yet to be determined in a longitudinal study, we propose 
that periodic assessment of pulmonary function tests including respiratory muscle strength 
measurements should be included in evaluation of CPEO patients.
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aBSTracT
Background: Renal involvement is a common feature in mitochondrial disorders. Children 
with mitochondrial disorders are especially at risk, whereas the extent of renal involve-
ment in adults with mitochondrial disorders is less established. We therefore performed a 
prospective study to determine the nature and frequency of renal involvement in a cohort 
of patients with genetically confirmed chronic progressive external ophthalmoplegia 
(CPEO), one of the commonest mitochondrial disorders in adulthood.
Methods: All 24 participants completed a questionnaire on urinary tract symptoms. We 
measured blood pressure, fasting glucose, assessed eGFR and micro-albuminuria as 
markers of glomerular damage and measured serum potassium, uric acid, phosphate and 
bicarbonate, and urinary alpha1-microglobulin as markers of tubular dysfunction.
Results: Five patients (21%) had evidence of tubular dysfunction (i.e. an increased urinary 
alpha1-microglobulin/creatinine ratio). However, four of these five patients had hyperten-
sion or diabetes mellitus, while the alpha1-microglobulin/creatinine ratio was correlated 
with the urinary albumin/creatinine ratio. Two patients had micro-albuminuria, associated 
with hypertension in both. Seven patients (29%) had hypertension and five (21%) diabetes 
mellitus, a known comorbidity in CPEO. Fourteen patients (58%) reported incontinence, 
mainly urge incontinence (10 patients, 42%)
Conclusions: Although we failed to detect clinically relevant renal involvement in our 
cohort, we did find a high prevalence of hypertension and diabetes mellitus. We therefore 
recommend routine evaluation of blood pressure and glucose, while screening for micro-
albuminuria and tubular dysfunction should be restricted to selected cases. Moreover, the 
cause of incontinence in CPEO is unknown and should be the focus of future study.
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InTroDucTIon
Mitochondrial disorders are the most common group of diseases among the inborn errors 
of metabolism, with an estimated overall incidence of approximately 1:5000 [1;2]. They 
comprise a genetically and clinically heterogeneous group of diseases, with manifesta-
tions ranging from adult-onset single organ dysfunction to severe neonatal multi-system 
failure.
One of the commonest mitochondrial disorders in adulthood is chronic progressive ex-
ternal ophthalmoplegia (CPEO). The defining clinical feature of CPEO is bilateral slowly 
progressive weakness of the extra-ocular muscles, resulting in drooping of the eyelids and 
restriction of movement of the eyeballs. In addition, various other organ systems can also 
be affected to various degrees, mainly the central nervous system, skeletal muscles, heart, 
peripheral nerves, retina, cochlea, and pancreatic beta-cells.
Renal tubuli have a very high ATP demand and tubular involvement is therefore likely 
in mitochondrial disorders. In CPEO patients there are indeed several reports of tubular 
dysfunction (the Toni-Debre-Fanconi syndrome [3], a Bartter-like syndrome [4;5], hypo-
magnesemia due to renal losses [6] or renal tubular acidosis [7]). Interestingly, all but 
one of the previously published CPEO patients with renal involvement had a phenotype 
compatible with the Kearns Sayre syndrome (KSS) [8], a CPEO subtype defined as a com-
bination of ophthalmoplegia, pigmented retinopathy, age of onset below 20 years, and 
at least one of the following symptoms: cardiac conduction block, cerebellar ataxia or 
elevated CSF protein content [9].
Despite these various case reports, the prevalence of clinically relevant kidney involve-
ment appears low since in the two largest published CPEO cohorts tubulopathy was 
reported in only 2 out of 91 patients [10;11]. This is in contrast with studies on other 
mitochondrial disorders, which found a prevalence of up to 50% in a pediatric population 
[12]. This discrepancy might be explained by the fact that renal involvement has never 
been systematically and prospectively studied in CPEO, resulting in an underestimation of 
subclinical or mild renal involvement. The aim of this study was therefore to prospectively 
investigate the prevalence and nature of renal involvement in an adult population of 
genetically confirmed CPEO patients.
PaTIenTS anD MeThoDS
Patients
All CPEO patients known in the Department of Neurology of the Radboud University 
Nijmegen Medical Centre were invited to participate. All had a phenotype including a 
slowly progressive bilateral external ophthalmoplegia and a proven pathogenic mutation 
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or deletion in the mitochondrial DNA or in one of the nuclear genes associated with 
CPEO. We considered KSS a CPEO subtype, not a distinct clinical entity [13]. Local ethical 
committee approved this study and all patients gave written informed consent according 
to the Declaration of Helsinki.
Methods
Patients’ characteristics
We measured blood pressure three times using a calibrated mercury manometer and 
calculated means. We performed routine neurological examination and systematically 
inquired about prior medical history and use of medication. Hypertension was defined as 
a mean systolic blood pressure > 140 mmHg and/or a mean diastolic blood pressure > 90 
mmHg and/or the use of antihypertensive medication. In addition, we measured fasting 
glucose and glycosylated haemoglobin (HbA1c) in venous plasma. Diabetes was defined 
as a fasting glucose ≥ 7.0 mmol/l and/or an HbA1c ≥ 6.5%.
Renal function assessment
We measured sodium, potassium, chloride, bicarbonate, phosphate, creatinine, albumin 
and uric acid in venous blood drawn from the antecubital vein. Albumin, alpha1-micro-
globulin, glucose, creatinine and pH were measured in fresh midstream urine samples. 
The glomerular filtration rate (eGFR) was estimated using the simplified MDRD formula 
[14].
In addition, we calculated the urine albumin/creatinine ratio (ACR) and the alpha1-
microglobulin/creatinine ratio (α1CR). Microalbuminuria was defined by an ACR ≥ 2.5 
mg/mmol in males and an ACR ≥ 3.5 mg/mmol in females.
Questionnaire
All participants completed a questionnaire on family history, voiding frequency, urinary 
incontinence and symptoms of urinary tract calculi. Results of ancillary investigations and 
of genetic investigations were derived from the patients’ files.
Statistical analysis
Data analysis was performed using SPSS (version 17.0). A Spearman coefficient was used 
to calculate correlations. A Mann Whitney test was used to compare means, a Fisher’s 
exact test to compare frequencies. Significance level was set at p<0.05 (two-tailed) in all 
cases.
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reSulTS
Patients’ characteristics
We identified 27 eligible patients. All were invited to participate. After agreeing to par-
ticipate a 54-year-old female patient with a mtDNA deletion died from sepsis before she 
was included in the study. Venapuncture was repeatedly unsuccessful in a 28-year-old 
female patient with a mtDNA deletion, while an 80-year-old male patient with compound 
heterozygous c.752C>T, c.1760C>T and c.2243G>C mutations in the POLG1 gene was 
unable to collect a fresh urine sample due to severe incontinence. These three patients 
were excluded from further analyses.
Of the remaining 24 patients (13 female, 11 male), mean age was 47.5 years (range 28-64) 
and mean age at onset was 21.0 years (range 5-48) (Table 1). Mutation type included a 
single mtDNA deletion in 16 patients (67%), a mtDNA point mutation in four (17%) and a 
POLG1 mutation in four (17%). POLG1 mutations included a homozygous A467T in two 
patients (21 and 22) and compound heterozygous A467T and W748S mutations in two 
others (patients 23 and 24). None of the patients had Twinkle or ANT1 mutations. Four 
patients met the criteria for KSS, three with a mtDNA deletion (patients 5, 15 and 16), and 
one with an m.03243A→G mutation (patient 19). The brother of patient 19 also carried 
the m.03243A→G mutation (patient 18).
Seven patients had hypertension, for which only one patient received treatment. Three 
patients were known diabetics, while two additional patients were newly diagnosed with 
diabetes: patient 13 had an increased fasting glucose (9.6 mmol/l) and patient 17 had an 
increased HbA1c (6.6%).
renal function
Laboratory test results are listed in Table 1. Although there were minor electrolyte distur-
bances in some patients, there was no evidence of clinically relevant renal involvement.
Renal function as defined by eGFR was normal in all patients. Two male patients (1 and 
17) had microalbuminuria (Table 1), both also had hypertension and a history of urinary 
tract calculi. Five patients had an increased α1CR (>1.5 mg /mmol), of whom three had 
hypertension, one had diabetes and one used NSAIDs daily. There was a significant cor-
relation between α1CR and ACR (rho=0.623, p=0.001).
Questionnaire
Incontinence was reported by 11 female (85%; stress incontinence in 4, urge in 4 and 
mixed incontinence in 3) and 3 male patients (27%, all urge). There was no relation 
between incontinence and age, age of onset or duration of disease. Neither urge nor stress 
incontinence was associated with any of the clinical features included in Table 1.
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Four patients (17%) reported a voiding frequency ≥ 10/day, including three patients (num-
ber 6, 20 and 24) with urge incontinence and one (19) with diabetes mellitus. Two patients 
(1 and 17) reported a history of urinary tract calculi. Two patients had a family history 
of renal disease: the mother of patient 13 had nephrotic syndrome, while the mother of 
patient 7 had diabetic nephropathy.
DIScuSSIon
In the present study, we systematically investigated potential renal involvement in an 
adult population of CPEO patients. We estimated GFR using serum creatinine, assessed 
micro-albuminuria as marker of glomerular (podocyte) damage and serum potassium, 
uric acid, phosphate and bicarbonate and urinary alpha1-microglobulin as markers of 
tubular dysfunction. In this cohort of 24 patients, we observed hypertension in seven 
patients and diabetes mellitus in five. Evidence of tubular dysfunction, as reflected by the 
increased α1CR ratio was seen in five patients. Four of these five patients had hypertension 
or diabetes mellitus. Two patients had micro-albuminuria, which could be attributed to 
hypertension in both cases. Moreover, there was a correlation between the α1CR and the 
ACR. Overall, this suggests that the observed abnormalities are most likely secondary to 
abnormal blood pressure and glucose regulation. Clearly, we failed to detect any kind 
of clinically relevant tubular involvement or decreased eGFR in our cohort. Even the 
patients with a KSS phenotype or with the m.03243A→G mutation had normal kidney 
function, despite the fact that both conditions have previously been associated with renal 
involvement. Admittedly, serum creatinine based formulas are not validated in patients 
with mitochondrial disorders, and it is likely that in such patients eGFR overestimates real 
GFR.
In mitochondrial disorders in general, the clinical features, age of onset, the progression 
and extent of organ involvement vary considerably. Organs most commonly affected 
in mitochondrial disorders include the central and peripheral nervous system, skeletal 
muscles, heart, cochlea, and retina [15]. Although there seems to be no apparent rela-
tion between these commonly affected organs, as a rule of the thumb, the susceptibility 
of tissues and cells to mitochondrial dysfunction largely depends on two factors [16]. 
First, since the main function of mitochondria is ATP production through oxidative phos-
phorylation, tissues with a high degree of oxidative phosphorylation are more susceptible 
to mitochondrial dysfunction. Second, tissues with a low mitotic activity are also more 
susceptible, especially in mtDNA mutations. The relation between mitotic activity and 
susceptibility to mitochondrial dysfunction is related on the fact that both normal and 
mutated mtDNA can coexist in one cell. During mitosis, normal and mutated mtDNA 
copies are randomly distributed over the two daughter cells. If by chance a daughter cell 
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receives only few mutated mtDNA copies, it is likely to survive whereas a daughter cell 
with a high percentage of mutated DNA will not. As a result, after several mitotic cycles, 
the percentage of mutated mtDNA decreases.
Based on these two factors kidneys are likely to be affected in mitochondrial disorders. 
First, renal oxidative phosphorylation activity is very high: kidneys make up only 1% of 
the body weight, but account for about 10% of the total body ATP turnover [17]. The 
proximal tubule in particular has very high oxidative activity. Second, the podocyte is 
post-mitotic, implying it has no mitotic activity at all [18]. Moreover, in addition to these 
theoretical considerations, the interest of nephrologists has been fostered by publications 
concerning the involvement of the kidneys in mitochondrial disorders [19;20].
There is a striking difference between the pediatric and adult population regarding renal 
involvement in mitochondrial disorders [21]. The most common presentation in childhood 
is dysfunction of the proximal tubule or the thick ascending limb, presenting as Fanconi 
or Bartter-like syndromes [3-5;12;22;23]. The pathophysiology of these syndromes in 
mitochondrial disorders is not established, but it is thought to result from deficient ATP 
production in the tubule cells. Proximal tubule dysfunction in mitochondrial disorders is 
often associated with multi-system involvement and has a poor prognosis.
In contrast, tubular dysfunction is uncommon in adults with mitochondrial disorders. 
Possibly, due to the regenerative capacity of the tubule epithelial cells, the percentage of 
mutated mtDNA decreases over time. As such, adults with mitochondrial disorders often 
present with signs of podocyte injury, mainly steroid resistant focal segmental glomerulo-
sclerosis (FSGS) [24-26]. Adults often have limited multi-organ involvement and a better 
prognosis. Only one gene mutation, the m.03243A→G mutation, has been associated 
with FSGS in adults and this particular mutation is by far the most common cause of renal 
disease in adults with mitochondrial disorders. The m.03243A→G mutation was first dis-
covered in patients with MELAS (mitochondrial encephalomyopathy, lactic acidosis, and 
stroke-like episodes), but later also in patients with CPEO or MIDD (maternally inherited 
diabetes and deafness). At present, it has become evident that the m.03243A→G mutation 
can also result in isolated renal disease in patients without signs of MELAS or MIDD, even 
after prolonged follow-up. The relation between the m.03243A→G mutation and renal 
disease is further illustrated by the fact that MIDD patients have a much higher rate of 
renal involvement than other diabetes patients and by a much higher prevalence of the 
m.03243A→G mutation in patients on dialysis than in the general population [27-29].
The m.03243A→G mutation alters the A14 nucleotide that is highly conserved in the 
tRNALeu(UUR). This mutation affects multiple pathways that can be traced to the destabiliza-
tion of structural features that destroy the tRNA conformation required for protein synthe-
sis efficiency, aminoacylation, post-transciptional modification and processing. Besides 
mutations in the mtDNA, nuclear gene defects may also cause renal disease. Over the last 
decade several novel gene defects resulting in kidney disease have been described and it 
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has become more evident that defects in several proteins involved in the mitochondrial 
energy generating system may cause various renal disorders (Table 2).
Despite the lack of specific renal involvement in our cohort, we did observe a high inci-
dence of hypertension. This may reflect subtle renal injury. In addition, more than one fifth 
of the patients had increased blood glucose levels. The high prevalence of hypertension 
and diabetes may justify regular evaluation for these cardiovascular risk factors in CPEO 
patients.
We also found a very high prevalence of both urge and stress incontinence. Although urge 
incontinence has previously been described in mitochondrial disorders, the underlying 
pathophysiological mechanism is unclear [30]. One might suggest, that urge incontinence 
results from impaired voiding control by the central nervous system. However, we did not 
find a relation between central nervous system involvement and urge incontinence in the 
present cohort. Stress incontinence on the other hand might result from pelvic muscles 
Table 2: Mutations associated with renal involvement in mitochondrial disorders
Associated genes Gene function
childhood presentation
 Tubulopathy mtDNA deletion [22;23;32] various genes
COX10 [33] Complex IV
BCS1L [34] Complex III
RRM2B [35] P53R2
 Tubular acidosis mtDNA deletion [7] various genes
 Focal segmental glomerulosclerosis m.03243A>G [36;37] tRNALeu(UUR)
m.05843A>G [38] Complex I
COQ2 [39] Coenzyme Q10
COQ6 [40] Coenzyme Q10
mtDNA deletion [41] various genes
 Tubulointerstitial nephropathy mtDNA deletion [42] various genes
m.00608A>G [43] Complex I
 Cystic renal disease m.12425A-del [44] Complex I
adult presentation
 Focal segmental glomerulosclerosis m.03243A>G [24-26] tRNALeu(UUR)
 Hypomagnesemia m.04291T>C [45] tRNAIle
 Tubulointerstitial nephropathy m.03243A>G [46] tRNALeu(UUR)
 Cystic renal disease m.03243A>G [46] tRNALeu(UUR)
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weakness, though incontinence due to myopathic weakness of the pelvic floor is uncom-
mon even in severe myopathies such as Duchenne muscular dystrophy [31]. Moreover, 
no association was found between stress incontinence and proximal muscle weakness or 
peripheral neuropathy in this study. Unfortunately, the present study was not designed to 
determine the pathophysiology of incontinence in CPEO and future studies should focus 
on this issue.
In conclusion, clinically relevant renal involvement, though common in mitochondrial 
disorders in general, is rare in adult CPEO. In contrast, hypertension and diabetes were 
common. We therefore recommend routine evaluation of blood pressure and glucose, 
while screening for microalbuminuria and tubular dysfunction should be restricted to 
selected cases.
94 Chapter 7
referenceS
 1. Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders 
in the West Midlands, UK. Arch Dis Child 2006; 91: 896-899
 2. Schaefer AM, Taylor RW, Turnbull DM, Chinnery PF. The epidemiology of mitochondrial 
disorders - past, present and future. Biochim Biophys Acta-Bioenergetics 2004; 1659: 115-120.
 3. Mori K, Narahara K, Ninomiya S, Goto Y, Nonaka I. Renal and skin involvement in a patient 
with complete Kearns-Sayre syndrome. Am J Med Genet 1991; 38: 583-587
 4. Goto Y, Itami N, Kajii N, Tochimaru H, Endo M, Horai S. Renal tubular involvement mimicking 
Bartter syndrome in a patient with Kearns-Sayre syndrome. J Pediatr 1990; 116: 904-910.
 5. Emma F, Pizzini C, Tessa A et al. “Bartter-like” phenotype in Kearns-Sayre syndrome. Pediatr 
Nephrol 2006; 21: 355-360
 6. Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathy-
roidism in Kearns-Sayre syndrome. Am J Nephrol 2001; 21: 150-153.
 7. Eviatar L, Shanske S, Gauthier B et al. Kearns-Sayre syndrome presenting as renal tubular 
acidosis. Neurology 1990; 40: 1761-1763
 8. Yuri T, Kondo Y, Kohno K et al. An autopsy case of chronic progressive external ophthalmople-
gia with renal insufficiency. Med Mol Morphol 2008; 41: 233-237.
 9. Lestienne P, Ponsot G. Kearns-Sayre syndrome with muscle mitochondrial-DNA deletion. 
Lancet 1988; 1: 885
 10. Aure K, Ogier de BH, Laforet P, Jardel C, Eymard B, Lombes A. Chronic progressive ophthal-
moplegia with large-scale mtDNA rearrangement: can we predict progression? Brain 2007; 
130: 1516-1524
 11. Bosbach S, Kornblum C, Schroder R, Wagner M. Executive and visuospatial deficits in patients 
with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Brain 2003; 
126: 1231-1240
 12. Martin-Hernandez E, Garcia-Silva MT, Vara J et al. Renal pathology in children with mito-
chondrial diseases. Pediatr Nephrol 2005; 20: 1299-1305.
 13. Smits BW, Fermont J, Delnooz CCS, Kalkman JS, Bleijenberg G, van Engelen BGM. Disease 
impact in chronic progressive external ophthalmoplegia: more than meets the eye. Neuromus-
cul Disord 2011; 21: 272-278
 14. Levey AS, Coresh J, Greene T et al. Expressing the MDRD study equation for estimating GFR 
with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005; 16: 69A
 15. Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: diagnosis and new 
treatments in mitochondrial diseases. J Neurol Neurosurg Psychiatry 2009; 80: 943-953
 16. DiMauro S, Schon EA. The mitochondrial respiratory chain and its disorders. In: DiMauro S, 
Hirano M, Schon EA, eds. Mitochondrial medicine. Informa Healthcare, Abingdon, UK: 2006; 
7-27
 17. Rotig A, Niaudet P. Mitochondrial nephrology. In: DiMauro S, Hirano M, Schon EA, eds. 
Mitochondrial medicine. Informa Healthcare, Abingdon, UK: 2006; 197-207
 18. Pabst R, Sterzel RB. Cell renewal of glomerular cell types in normal rats. An autoradiographic 
analysis. Kidney Int 1983; 24: 626-631
 19. Mochizuki H, Joh K, Kawame H et al. Mitochondrial encephalomyopathies preceded by de-
Toni-Debre-Fanconi syndrome or focal segmental glomerulosclerosis. Clin Nephrol 1996; 46: 
347-352
Renal involvement in adult chronic progressive external ophthalmoplegia, a mitochondrial myopathy 95
 20. Jansen JJ, Maassen JA, van der Woude FJ et al. Mutation in mitochondrial tRNA(Leu(UUR)) 
gene associated with progressive kidney disease. J Am Soc Nephrol 1997; 8: 1118-1124
 21. Hall AM, Unwin RJ, Hanna MG, Duchen MR. Renal function and mitochondrial cytopathy 
(MC): more questions than answers. QJM 2008; 101: 755-766
 22. Campos Y, Garcia-Silva T, Barrionuevo CR, Cabello A, Muley R, Arenas J. Mitochondrial DNA 
deletion in a patient with mitochondrial myopathy, lactic acidosis, and stroke-like episodes 
(MELAS) and Fanconi’s syndrome. Pediatr Neurol 1995; 13: 69-72
 23. Pitchon EM, Cachat F, Jacquemont S et al. Patient with Fanconi syndrome (FS) and retinitis 
pigmentosa (RP) caused by a deletion and duplication of mitochondrial DNA (mtDNA). Klin 
Monbl Augenheilkd 2007; 340-343
 24. Lowik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial 
tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal 
segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20: 336-341
 25. Doleris LM, Hill GS, Chedin P et al. Focal segmental glomerulosclerosis associated with 
mitochondrial cytopathy. Kidney Int 2000; 58: 1851-1858
 26. Kurogouchi F, Oguchi T, Mawatari E et al. A case of mitochondrial cytopathy with a typical 
point mutation for MELAS, presenting with severe focal segmental glomerulosclerosis as main 
clinical manifestation. Am J Nephrol 1998; 18: 551-556
 27. Guillausseau PJ, Massin P, Dubois-LaForgue D et al. Maternally inherited diabetes and deaf-
ness: A multicenter study. Ann Intern Med 2001; 134: 721-728
 28. Iwasaki N, Babazono T, Tsuchiya K et al. Prevalence of A-to-G mutation at nucleotide 3243 of 
the mitochondrial tRNA(Leu(UUR)) gene in Japanese patients with diabetes mellitus and end 
stage renal disease. J Hum Genet 2001; 46: 330-334
 29. Manwaring N, Jones MM, Wang JJ et al. Population prevalence of the MELAS A3243G muta-
tion. Mitochondrion 2007; 7: 230-233
 30. Safir MH, Gousse AE, Cederbaum SD, Raz S. Voiding dysfunction in a mother and daughter 
with mitochondrial cytopathy. J Urol 1998; 160: 830
 31. Caress JB, Kothari MJ, Bauer SB, Shefner JM. Urinary dysfunction in Duchenne muscular 
dystrophy. Muscle Nerve 1996; 19: 819-822
 32. Majander A, Suomalainen A, Vettenranta K et al. Congenital hypoplastic anemia, diabetes, 
and severe renal tubular dysfunction associated with a mitochondrial-DNA deletion. Pediatr 
Res 1991; 30: 327-330
 33. Valnot I, von Kleist-Retzow J-C, Barrientos A et al. A mutation in the human heme A: farnesyl-
transferase gene (COX10) causes cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9: 
1245-1249
 34. de Lonlay P, Valnot I, Barrientos A et al. A mutant mitochondrial respiratory chain assembly 
protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver 
failure. Nat Genet 2001; 29: 57-60
 35. Bourdon A, Minai L, Serre V et al. Mutation of RRM2B, encoding p53-controlled ribonucleo-
tide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet 2007; 39: 
776-780
 36. Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic 
features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene muta-
tion. Kidney Int 2001; 59: 1236-1243
 37. Cheong HI, Chae JH, Kim JS et al. Hereditary glomerulopathy associated with a mitochondrial 
tRNA(Leu) gene mutation. Pediatr Nephrol 1999; 13: 477-480
96 Chapter 7
 38. Scaglia F, Vogel H, Hawkins EP, Vladutiu GD, Liu LL, Wong LJC. Novel homoplasmic muta-
tion in the mitochondrial tRNA(Tyr) gene associated with atypical mitochondrial cytopathy 
presenting with focal segmental glomeruloselerosis. Am J Med Genet A 2003; 123A: 172-178
 39. Quinzii C, Naini A, Salviati L et al. A mutation in para-hydroxybenzoate-polyprenyl transfer-
ase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006; 78: 345-349
 40. Heeringa SF, Chernin G, Chaki M et al. COQ6 mutations in human patients produce nephrotic 
syndrome with sensorineural deafness. J Clin Invest 2011; 121: 2013-2024
 41. Unal S, Kalkanoglu HS, Kocaefe C et al. Four-month-old infant with focal segmental glomeru-
losclerosis and mitochondrial DNA deletion. J Child Neurol 2005; 20: 83-84
 42. Szabolcs MJ, Seigle R, Shanske S, Bonilla E, DiMauro S, Dagati V. Mitochondrial DNA dele-
tion - a cause of chronic tubulointerstitial nephropathy. Kidney Int 1994; 45: 1388-1396
 43. Tzen CY, Tsai JD, Wu TY et al. Tubulointerstitial nephritis associated with a novel mitochon-
drial point mutation. Kidney Int 2001; 59: 846-854
 44. Alston CL, Morak M, Reid C et al. A novel mitochondrial MTND5 frameshift mutation causing 
isolated complex I deficiency, renal failure and myopathy. Neuromuscul Disord 2010; 20: 
131-135
 45. Wilson FH, Hariri A, Farhi A et al. A cluster of metabolic defects caused by mutation in a 
mitochondrial tRNA. Science 2004; 306: 1190-1194
 46. Guery B, Choukroun G, Noel LH et al. The spectrum of systemic involvement in adults pre-
senting with renal lesion and mitochondrial tRNA(Leu) gene mutation. J Am Soc Nephrol 
2003; 14: 2099-2108
Part IV
Summary and discussion

Chapter 8
Summary and discussion

Summary and discussion 101
general conSIDeraTIonS
Our understanding of mitochondrial genetics and function has greatly increased over 
the last two to three decades. The care of patients with mitochondrial disorders has also 
improved due to increased knowledge of the natural course of various mitochondrial 
disorders, the development of diagnostic guidelines and by more advanced genetic assays 
[1;2]. Moreover, several therapeutic strategies have been developed, including l-arginine 
in stroke-like episodes associated with MELAS, co-enzyme Q10 in primary co-enzyme 
Q10 deficiency and bone marrow transplant or dialysis in MNGIE patients [3-5]. Unfor-
tunately, causative treatment is not available for most mitochondrial disorders, nor is it 
expected in the near future [6]. At present, the management of patients with mitochondrial 
disorders is therefore largely symptomatic, attempting to minimize the impact of the dis-
ease on patients’ functioning.
Symptomatic management aimed at the specific needs of the individual patients how-
ever requires awareness of the signs and symptoms, the natural course and the disease 
impact. In this thesis we therefore systematically studied the phenotype and impact of 
disease in one of the commonest mitochondrial disorders, chronic progressive external 
ophthalmoplegia (CPEO). In addition, we evaluated the effectiveness of the diagnostic 
workup in patients with a suspected mitochondrial disorder, as patients’ management 
obviously requires the confirmation of a correct diagnosis. Ultimately, the conclusions of 
this thesis could help physicians to optimize the diagnostic process and to provide more 
effective symptomatic management to patients with a mitochondrial disorder. Below, a 
short summary of previous chapters is provided in boxes and the results are discussed in 
more detail.
SuMMarIeS
After the Introduction (Part I), we provide several considerations for the workup of a sus-
pected mitochondrial disorder in Part II (chapters 2 and 3). chapter 2 discusses the extent 
of mitochondrial involvement in chronic fatigue syndrome (CFS), as well as the value of 
measurement of respiratory chain complex (RCC) activities in the discrimination between 
CFS and mitochondrial disorders. Identifying procedures to discriminate between CFS 
and mitochondrial disorders can improve the diagnostic process in patients presenting 
with non-specific features such as fatigue, exercise intolerance and myalgia, which are 
common in both disorders [7;8].
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Summary chapter 2
We determined the extent of mitochondrial dysfunction in CFS patients and found 
that CFS patients had a significantly lower skeletal muscle mitochondrial content than 
controls. When corrected for mitochondrial content, the mitochondrial RCC activities 
did not differ between the two groups.
Next, we investigated whether measurement of RCC activities discriminated between 
patients with CFS and patients with mitochondrial disorders. Mitochondrial content 
did not discriminate between CFS and mitochondrial disorders, but respiratory chain 
complexes I, III and IV and the ATP production did, all with lower activities in the 
patients with mitochondrial disorders.
The interpretation of the decreased mitochondrial content in skeletal muscle of CFS is 
difficult. One could argue that decreased mitochondrial content is the cause of CFS and 
therefore of symptoms such as fatigue, exercise intolerance and exercise induced myalgia. 
However, one could also argue that decreased mitochondrial content is the consequence 
of physical inactivity, which is a common feature in CFS. The latter concept is supported 
by studies that found a decreased mitochondrial content in healthy but physically inac-
tive subjects, and an increase in mitochondrial content in response to training [9-12]. 
Additional studies are required to elucidate whether decreased mitochondrial content 
is cause or consequence of CFS. For this purpose, it would be worthwhile to determine 
whether the relation between physical activity and mitochondrial content is continuous 
or mitochondrial content decreases only when the degree of physical inactivity reaches a 
certain threshold. It would be interesting to investigate the effect of cognitive behavioral 
therapy (CBT) on mitochondrial content in CFS patients. CBT is an established treatment 
in CFS [13]. It results in an increase in physical functioning and ameliorates fatigue [14]. 
Should mitochondrial content increase in response to a successful treatment with CBT, it 
is reasonable to assume that decreased mitochondrial content in CFS is the consequence 
of physical inactivity rather than the cause.
In the second part of the study we discuss the use of RCC measurement in the diagnostic 
workup of patients with nonspecific neuromuscular complaints such as fatigue, exercise 
intolerance and exercise induced myalgia. Although these non-specific complaints may 
be the sole manifestations of a mitochondrial disorder, often no underlying somatic disor-
der is found and patients are consequentially considered to have CFS [7]. Differentiation 
between a mitochondrial disorder and CFS is often troublesome, especially when skeletal 
muscle histology or evaluation of mtDNA in leukocytes fails to confirm the diagnosis of a 
mitochondrial disorder. RCC measurement in skeletal muscle may then be performed for 
further differentiation, though the discriminative value has never been established [15]. In 
chapter 2, we demonstrated that measurement of RCC activities can reliably be used to 
discriminate between CFS and a mitochondrial disorder. The ATP production rate, which 
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can only be measured in a fresh muscle biopsy, was shown to have the highest discrimina-
tive value.
Although chapter 2 underlines the use of RCC measurement in the workup of a sus-
pected mitochondrial disorder, the most definite proof of a mitochondrial disorder is the 
detection of a known pathogenic DNA mutation. In CPEO, a large variety of pathogenic 
mtDNA point mutations and large scale rearrangements have previously been reported 
(see chapter 1, Table 3). The CPEO patient in chapter 3 was found to have a pathogenic 
mtDNA point mutation, which had not previously been associated with CPEO [16].
Summary chapter 3
We found a heteroplastic m.04267A→G mutation in the mitochondrial tRNAIle in a 
52-year-old patient with a five year history of progressive external ophthalmoplegia and 
exercise induced muscle cramps. This specific mutation had been described only once 
before in another phenotype: a patient with deafness, cerebellar dysarthria, muscle 
ache, fatigue and mental slowing, but no signs of external ophthalmoplegia.
The discovery of a new mtDNA point mutation is often associated with some degree of 
uncertainty whether the mutation is the actual cause of the phenotype or a coincidental 
non-pathogenic polymorphism. The fact that we found the m.04267A→G mutation in a 
patient with CPEO, which is an established mitochondrial phenotype, provides additional 
evidence for its pathogenicity. Moreover, our findings support the approach of total mtDNA 
sequencing in cases of CPEO that are not due to large scale mtDNA rearrangements.
In Part III (chapters 4 to 7), we describe the results of four studies on various aspects of 
the CPEO phenotype. The results of a study on the disease impact associated with CPEO 
are summarized in chapter 4.
Summary chapter 4
We determined the disease impact in 28 patients with genetically confirmed CPEO 
and compared the outcomes to those of matched myotonic dystrophy type I (DM1) 
patients. CPEO patients reported a high frequency of severe fatigue (68%), pain (96%), 
depression (32%) and dependence in daily life (46%). All of these aspects of disease 
impact were significantly more severe than in the DM1 cohort. CPEO patients with 
polymerase gamma 1 (POLG1) mutations reported more functional impairments than 
those with mitochondrial DNA mutations, whereas most of the clinical features did not 
influence disease impact.
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This study identifies fatigue, depression, pain, and functional impairments as the main 
aspects of disease impact in CPEO and thus helps to provide symptomatic management of 
the specific needs of the individual patient. As such, the treatment of depression may be 
of particular interest, since it was associated with functional impairments and decreased 
independence. Treatment of depression might therefore ideally result in an increase of 
functional capacities. However, the cross sectional design of our study does not allow to 
determine whether depression is the cause or consequence of functional impairments. 
Moreover, depression in mitochondrial disorders most likely results from mitochondrial 
dysfunction in the frontal lobes [17-19]. The pathogenesis of depression is therefore pos-
sibly different in patients with mitochondrial disorders than in the general population. 
Consequently, the beneficial effect of antidepressants is uncertain in patients with mito-
chondrial disorders.
A greater emphasis on the treatment of pain may also be warranted. Pain was both com-
mon and severe in our cohort, despite the use of analgesics by a majority of patients. This 
might indicate that CPEO patients are either refractory to analgesics or that they are often 
undertreated. The latter is supported by the fact that despite the severity of pain only two 
patients used opioids.
Treatment of fatigue will also likely improve well-being. To date, aerobic training is the 
only therapy with an evidence based beneficial effect on fatigue in mitochondrial patients 
[20]. However, the three to four times weekly cycle schedule is demanding and therefore 
not feasible for patients with advanced disease. Since fatigue is such a major symptom in 
CPEO, it is desirable to study the effect of other treatments, such as cognitive behavioral 
therapy and/or pharmacological interventions such as amantadine.
In chapter 5, we describe the prevalence and determinants of sleep disturbances in CPEO.
Summary chapter 5
We assessed the prevalence and determinants of sleep disturbances in 20 genetically 
confirmed CPEO patients. Using questionnaires, we found that 75% reported nocturnal 
sleep dysfunction, partly associated with anxiety. Thirty-five percent fulfilled the criteria 
for restless legs syndrome and 30% had excessive daytime sleepiness. Polysomnography 
revealed several indicators of a disrupted sleep architecture: 70% had significant peri-
odic limb movements, while 4 patients, all with POLG1-mutations, had an increased 
central sleep apnea index. Obstructive sleep disordered breathing was present in only 
one patient. Physical examination and questionnaire outcomes were poor predictors of 
polysomnography results.
This study demonstrates that several specific sleep disturbances are part of the CPEO 
phenotype. Sleep disturbances are important to recognize, as they have a profound nega-
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tive impact on the quality of life. Identifying CPEO patients at risk for a sleep disorder may 
however be complicated, since subjective sleep quality and clinical features were poor 
predictors of polysomnography outcomes. From a practical point of view, it seems reason-
able to perform a polysomnography only in patients with symptoms of impaired sleep, 
as they are the ones that might benefit from treatment of the underlying sleep disorder. 
The common therapeutic options for sleep disorders, e.g. positive airway pressure for 
sleep apnea and dopamine agonists or gabapentin for restless legs and periodic limb 
movements, are safe and non-invasive and can therefore be used empirically in individual 
patients. However, the effectiveness of these treatments in patients with mitochondrial 
disorders should preferably be determined in a clinical trial. The end points in such a trial 
should not only be the improvement of the apnea and limb movement index or the quality 
of sleep, but also the perception of health and quality of life in general.
chapter 6 describes the nature and frequency of respiratory involvement in CPEO.
Summary chapter 6
We determined the prevalence, nature and determinants of respiratory muscle involve-
ment in 23 patients with genetically confirmed CPEO. The main finding was decreased 
respiratory muscle strength, both expiratory (76.8% of predicted) and inspiratory 
(79.5% of predicted). Inspiratory vital capacity (92.5% of predicted) and the forced 
expiratory volume in 1 second (89.3% of predicted) were also decreased. Expiratory 
weakness was associated with a decreased vital capacity and a decreased peak expira-
tory flow. Moreover, expiratory muscle strength was lower in patients with limb girdle 
weakness than in patients with normal limb girdle strength. Other clinical features 
such as subjective respiratory complaints, disease severity or disease duration were not 
associated with respiratory muscle weakness.
This study indicates that respiratory muscle weakness is common in CPEO. Since respira-
tory weakness is associated with an increased chance of pneumonia in other myopathies, 
the risk of pneumonia should theoretically also be increased in CPEO [21]. However, the 
majority of patients in our cohort had no history of pneumonia. This might be explained 
by a high mortality rate of pneumonias in CPEO. To test this hypothesis, we reviewed our 
files of all deceased CPEO patients and found that two out of the three patients with a 
confirmed cause of death indeed died as a direct result of their first pneumonia. Neverthe-
less, it would be desirable to study the relation between respiratory weakness and the risk 
of pneumonia in a longitudinal study.
It is tempting to speculate about the role of respiratory muscle weakness on exercise intol-
erance, which is one of the key symptoms in mitochondrial disorders. Exercise intolerance 
in mitochondrial myopathies is generally assumed to result from insufficient ATP produc-
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tion in skeletal muscles, causing premature fatigue, weakness and myalgia [22]. Previous 
studies on exercise capacity in patients with mitochondrial disorders however found an 
association between respiratory muscle weakness and decreased maximal minute ventila-
tion with rapid shallow breathing [23]. Respiratory muscle weakness may therefore be an 
independent factor in the pathogenesis of exercise intolerance in mitochondrial disorders. 
Should future research confirm this hypothesis, it would be worthwhile to investigate the 
effect of respiratory muscle training on both respiratory muscle strength and on exercise 
capacity. Lastly, respiratory muscle strength may prove to be a useful outcome measure in 
future intervention trials, since it is cheap, reproducible and easily obtainable.
In chapter 7, we describe the results of our study on renal involvement in CPEO.
Summary chapter 7
We determined the nature and frequency of renal involvement in 24 patients with 
genetically confirmed CPEO. Five patients (21%) had evidence of tubular dysfunc-
tion, though this could be attributed to hypertension or diabetes mellitus in four. Two 
patients (8%) had micro-albuminuria, associated with hypertension in both. Seven 
patients (29%) had hypertension and five (21%) diabetes mellitus. Fourteen patients 
(58%) reported incontinence, mainly urge incontinence (10 patients, 42%).
This study failed to detect any kind of clinically relevant renal involvement in our cohort. 
Nevertheless, we did find a high prevalence of hypertension and diabetes mellitus. We 
therefore recommend routine evaluation of blood pressure and glucose. Screening for 
microalbuminuria and tubular dysfunction should be restricted to selected cases.
Incontinence was very common in CPEO. Unfortunately, the present study was not de-
signed to determine the pathophysiology of the incontinence in CPEO and future studies 
should focus on this issue.
The absence of renal involvement in our cohort provides an interesting view on the CPEO 
phenotype. Based on theoretical considerations and on the fact that renal involvement is 
common in other mitochondrial disorders one would expect to have found renal involve-
ment in the present CPEO cohort. The absence of renal involvement in our cohort therefore 
indicates that despite the large overlap in clinical features between various mitochondrial 
disorders, the CPEO phenotype has a specific phenotypical “fingerprint”.
Combining the results of all previous chapters, some clinical features appear to be re-
lated to a particular genotype: sensory atactic neuropathy and central sleep apneas were 
exclusively found in patients with POLG1-mutations, while clinically relevant expiratory 
muscle weakness was found in patients with mtDNA deletions only. Moreover, patients 
with POLG1-mutations had a higher rate of disease progression (i.e. more functional 
impairment), despite a higher age at disease onset.
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oVerVIeW
This thesis addresses two aspects of the care for mitochondrial patients. First, it provides 
important clues to improve the diagnostic workup of patients with a suspected mitochon-
drial disorder. Second, it draws attention to the various symptoms in these multi-system 
disorders. This may allow for a more effective diagnostic workup, better symptomatic 
management and more efficient (multidisciplinary) follow-up of patients with CPEO.
To facilitate the care for a patient with (suspected) CPEO, several elements of this thesis 
have been summarized in a diagnostic algorithm and a guideline for patient management. 
The diagnostic algorithm and guideline are not only based on the data from the studies in 
this thesis, but also on our personal experience with CPEO patients, as well as on previous 
literature [24;25].
Diagnostic algorithm for (suspected) cPeo
As stated in chapter 1, a slowly progressive bilateral external ophthalmoplegia is a very 
specific clinical feature, with a limited differential diagnosis. In addition to CPEO, a slowly 
progressive bilateral external ophthalmoplegia can be caused by oculopharyngeal muscle 
dystrophy (OPMD), myasthenia gravis (MG) and congenital myasthenic syndromes (CM). 
Most cases of OPMD can likely be differentiated from CPEO by family history (autosomal 
dominant inheritance and late onset in OPMD) and most cases of MG and CM by course 
and history (marked fluctuations in muscle weakness, no extra-muscular symptoms, early 
age of onset in CM) and by repetitive nerve stimulation. When a fair degree of suspicion 
of CPEO remains, the following algorithm can help to confirm the diagnosis without un-
necessary (and invasive) ancillary investigations.
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m.03243AG mutation 
(leukocytes, urine sediment 
or hair follicles) 
Screen for specific mutation 
in appropriate tissue 
Quadriceps muscle biopsy 
(preferably needle biopsy) 
 
Histology 
- ≥ 2% RRFs  
         and/or 
- ≥ 2% COX- (age < 50 y) 
             or 
- ≥ 5% COX- (age > 50 y) 
 
Mitochondrial DNA 
-if available: mtDNA sequencing 
-otherwise: 
-blot for deletions 
-if negative: screen for      
pathogenic point mutations 
 
 
Deletion (single or multiple) 
or pathogenic point mutation 
Diagnosis CPEO 
confirmed 
Multiple mtDNA 
deletions 
1) Known 
mutation? 
no 
yes 
2) Positive for 
MELAS or 
MIDD? 
 
yes 
3) Autosomal 
dominant 
inheritance or 
SANDO 
phenotype 
 
yes 
no 
Positive family 
history or SANDO 
phenotype? yes 
absent no 
no 
absent 
POLG1, 
-if negative: Twinkle and OPA1 
-if negative:  
   consider ANT1, RRM2B, POLG2 
present 
present 
present 
POLG1, 
-if negative: Twinkle and OPA1 
-if negative:  
   consider ANT1, RRM2B, POLG2 
absent 
COX-, cytochrome c oxidase negative fibers; MELAS, mitochondrial encephalomyopathy - lactic 
acidosis - and stroke-like episodes; MIDD, maternally inherited diabetes and deafness; mtDNA, 
mitochondrial DNA; RRF, ragged red fibers, SANDO, sensory atactic neuropathy - dysarthria and 
ophthalmoplegia
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Suggested workup after confirmation of cPeo diagnosis
•	 Inquire	about	complaints	of	dysphagia,	hearing	loss,	depression,	periodic	leg	move-
ments, sleep apnea, restless legs, incontinence, palpitations and (near)collaps
•	 Blood	pressure	measurement
•	 Assessment	of	body	mass	index
•	 Blood	tests
 o  Full blood count, fasting glucose, potassium, creatinine, calcium, phosphorus, 
magnesium, uric acid, bicarbonate, albumin, PTH, TSH
 o  LH, FSH and oestrogen in premenopausal female patients
 o  LH, FSH and testosterone in male patients
 o  Growth hormone in patients with short stature or growth retardation
•	 Urine	albumin/creatinine	ratio
•	 Spirometry	including	measurement	of	respiratory	muscle	strength
•	 Evaluation	by	a	cardiologist,	including	an	echocardiography	and	EKG*
•	 Evaluation	by	a	rehabilitation	physician**
* Holter monitoring in patients with palpitations, (near)collaps or an abnormal EKG
**  Consider an aerobic training program for patients in good clinical condition, consultation of a 
physiotherapist for optimizing balance or cough technique, speech therapy in case of dysarthria or 
dysphagia and occupational therapy to increase independence
In selected cases, consider consulting
•	 Ear-nose-throat	physician:	hearing	loss,	dysphagia
•	 Ophthalmologist:	ptosis	surgery,	evaluation	of	retinal	involvement
•	 Genetic	counseling
•	 Psychiatrist:	depression,	anxiety
•	 Nephrologist:	renal	involvement
•	 Urologist:	incontinence
•	 Endocrinologist:	diabetes	mellitus,	other	endocrine	disorders
•	 Dietitian:	overweight	or	underweight
•	 Polysomnography:	suspected	sleep	disorder
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follow up
Annually
•	 Evaluation	by	a	neurologist
•	 Inquire	about	complaints	of	dysphagia,	hearing	loss,	depression,	periodic	leg	move-
ments, sleep apnea, restless legs, incontinence, palpitations and (near) collaps
•	 Blood	pressure
•	 Assessment	of	body	mass	index
•	 Fasting	glucose
•	 In	patients	with	previous	evidence	of	renal	involvement:	serum	potassium,	creati-
nine, calcium, phosphorus, magnesium, uric acid, bicarbonate, albumin and urine 
albumin/creatinine ratio
•	 EKG*
•	 Evaluation	by	rehabilitation	physician**
Biennially
•	 Blood	tests
 o  Full blood count, PTH, TSH
 o  LH, FSH and oestrogen in premenopausal female patients
 o  LH, FSH and testosterone in male patients
 o  Growth hormone in patients with short stature or growth retardation
•	 Urine	tests:	albumin/creatinine	ratio
•	 Spirometry	including	measurement	of	respiratory	muscle	strength
•	 Echocardiography
* Holter monitoring in patients with palpitations, (near)collaps or an abnormal EKG
**  Consider an aerobic training program for patients in good clinical condition, consultation of a 
physiotherapist for optimizing balance or cough technique, speech therapy in case of dysarthria or 
dysphagia and occupational therapy to increase independence
fuTure PerSPecTIVeS
Mitochondria in the chronic fatigue syndrome
In chapter 2, we demonstrated that mitochondrial content in skeletal muscle is less in 
patients with chronic fatigue syndrome than in healthy controls, whereas mitochondrial 
function remains unaffected. Our results are in concordance with previous studies that 
found decreased mitochondrial content in healthy but physically inactive subjects, and an 
increase in mitochondrial content in response to training.
Summary and discussion 111
More insight into the cellular and molecular pathways underlying the relation between 
mitochondrial content and physical activity may lead to a better understanding of the 
pathogenesis of CFS. Moreover, manipulation of the affected pathways may be a key to a 
pharmacological treatment not only for CFS, but also for mitochondrial disorders or sarco-
penia associated with aging or with long term immobility (e.g. in the intensive care unit).
Regarding the relation between physical activity and mitochondrial content or function, 
CFS is highly suitable as a model of inactivity. By definition, any underlying medical 
condition must be excluded in CFS. It is therefore reasonable to assume, that all effects on 
mitochondrial content and function result from alterations in the level of physical activity. 
Moreover, physical inactivity in CFS is reversible, as both cognitive behavioral therapy 
and graded exercise have a proven beneficial effect on physical activity in CFS patients.
It would therefore be worthwhile to investigate whether an increase in physical activity 
in CFS patients successfully treated with behavioral therapy coincides with an increase 
in mitochondrial content and function and/or upregulation of the pathways involved in 
mitochondrial biogenesis, such as PGC-1alpha (peroxisome proliferator-activated recep-
tor γ coactivator α) or TFAM (transcription factor A, mitochondrial).
The cPeo phenotype
This thesis illustrates the impact of disease and the extent of involvement of various organ 
systems. All data are however cross-sectional. The evolution of existing symptoms and 
the rate of occurrence of new symptoms over time are therefore unknown. A follow-up 
study on the same cohort could provide this information and thus allow for better patient 
counseling and management.
Therapy
To date, apart from aerobic training, there are no therapeutic interventions with a proven 
beneficial effect on the symptoms and course of CPEO. Management is therefore largely 
symptomatic, together with interventions aimed at limiting the detrimental effects of 
organ dysfunction. Several symptoms identified by the present studies have evidence 
based effective therapies in the general population. These include optimal analgesia in 
pain, antidepressants in depression, dopamine agonists for restless legs and periodic leg 
movement disorder, positive airway pressure therapy for central apnea during sleep and 
amantadine for fatigue. Whether these treatments are also effective in CPEO is unclear and 
this should preferably be established in a research setting.
Lastly, we found a high frequency of incontinence in our cohort. Incontinence is con-
sidered to have a profound negative impact on the quality of life. There are however 
several effective conservative, medical and surgical therapies for both stress and urge 
incontinence. The optimal approach towards incontinence in CPEO requires additional 
research on its pathophysiology.
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achTergronD
Dit proefschrift gaat over de ziekte chronische progressieve externe oftalmoplegie, kortweg 
CPEO. De naam verraadt enkele belangrijke kenmerken van de ziekte. Extern betekent 
buitenzijde en oftalmoplegie betekent verlamming van de ogen. Bij een externe oftalmo-
plegie raken de spieren aan de buitenkant van de oogbol dus verlamd. Hierdoor kunnen 
patiënten niet meer goed zijwaards, naar boven en naar beneden kijken. Ook de spieren, 
die de oogleden naar boven ophouden worden zwakker. De oogleden hangen hierdoor 
over de oogbollen (Figuur 1). Verder is CPEO chronisch, wat betekent dat de verschijnselen 
blijvend zijn en progressief, wat inhoudt, dat de ziekte in de loop der jaren steeds erger 
wordt. Vaak hebben CPEO patiënten meer klachten dan alleen een oogspierverlamming. 
Andere spieren kunnen ook zwak zijn, vooral in bovenarmen en –benen, de hartspier 
en de spieren in de keel, die zorgen voor het slikken. Blindheid en doofheid kunnen 
ook voorkomen. Verder hebben sommige patiënten een slechte coördinatie, vanwege niet 
goed werkende kleine hersenen, of een aantasting van de zenuwen, wat leidt tot minder 
gevoel in de voeten en handen. Tot slot komen problemen met de hormoonhuishouding 
vaak voor, zoals suikerziekte of een te traag werkende (bij)schildklier.
CPEO is een zeldzame ziekte. Het komt bij ongeveer 1 op de 40.000 mensen voor, zowel 
bij mannen als vrouwen. De leeftijd waarop de eerste klachten beginnen is heel wis-
selend. Sommige mensen hebben al vanaf de vroege jeugd klachten, terwijl anderen pas 
na hun vijftigste klachten krijgen.
CPEO is een energiestofwisselingsziekte. Alle cellen in ons lichaam verbruiken energie: 
een spiercel heeft energie nodig om samen te trekken, een schildkliercel om hormoon 
te kunnen uitscheiden en een zenuwcel om elektrische stroompjes op te kunnen wek-
ken. De energie, die hier voor nodig is, wordt geleverd in de vorm van ATP. ATP is een 
figuur 1
120 Chapter 9
klein molecuul, dat wordt gemaakt van suikers of vetten. De cel heeft hiervoor aparte 
“orgaantjes”, mitochondriën genaamd. Cellen die veel energie gebruiken hebben meer 
mitochondriën dan cellen met een laag energieverbruik. Bij CPEO werken de mitochon-
driën niet goed. Het wordt daarom gerekend tot de groep van mitochondriële ziekten.
Door wetenschappelijk onderzoek is er in de laatste 20 tot 30 jaar veel meer duidelijk ge-
worden over mitochondriën en mitochondriële ziekten. De code van het erfelijk materiaal 
(DNA) van mitochondriën is helemaal ontrafeld. Ook weten we, dat bepaalde foutjes in dit 
DNA, mutaties genoemd, kunnen leiden tot verschillende mitochondriële ziektes. Door 
nieuwe technieken is het de laatste jaren mogelijk geworden het hele mitochondriële 
DNA in een keer op mutaties te onderzoeken. Dit maakt het mogelijk om steeds sneller 
en nauwkeuriger de juiste diagnose te stellen. Ook is er uitgebreid onderzoek gedaan naar 
behandelingen. Helaas is er voor de meeste mitochondriële ziekten nog geen genezing 
mogelijk. De behandeling van patiënten met mitochondriële ziekten is tot nu toe dan 
ook vooral “symptomatisch”. Dit betekent dat er naar wordt gestreefd de beperkingen en 
klachten die de ziekte veroorzaakt zo veel mogelijk terug te brengen.
De optimale symptomatische behandeling voor een bepaalde klacht kan per ziekte ver-
schillen. Het is dan ook belangrijk dat eerst de juiste diagnose wordt gesteld. Verder moet 
het duidelijk zijn welke klachten het meest hinderlijk zijn in het dagelijks functioneren en 
welke organen precies betrokken kunnen zijn.
In het geval van CPEO weten we bijvoorbeeld dat spierzwakte vaak voorkomt, en 
dan vooral rond de ogen, in het hart, de keel en in de bovenarmen en -benen. Of de 
ademhalingsspieren ook zwak zijn is daarentegen niet bekend. Ook weten we niet hoe 
vaak problemen met de nieren voorkomen en of CPEO leidt tot een slechtere slaap. Tot 
slot is nog nooit onderzocht hoe CPEO patiënten hun ziekte ervaren en wat hun be-
langrijkste klachten zijn. Voor een goede symptomatische behandeling is het natuurlijk 
wel van belang om dit te weten. De behandelend arts kan immers alleen die klachten 
verlichten, waarvan hij weet dat ze er zijn.
Met dit proefschrift wilden we twee hoofdvragen beantwoorden. Eerst hebben we gekeken 
hoe bij een patiënt met verdenking op een mitochondriële ziekte het stellen van de juiste 
diagnose nog beter kan. Ten tweede hebben we onderzocht, welke klachten CPEO patiën-
ten eigenlijk hebben in het dagelijk functioneren en welke organen er precies aangedaan 
zijn.
heT STellen Van De juISTe DIagnoSe
In de mitochondriën loopt de omzetting van suikers en vetten in ATP via vier enzymen, 
complex I, II, III en IV genoemd. In het laboratorium kunnen deze enzymcomplexen wor-
den doorgemeten. Dit kan het beste in een klein stukje spier, wat uit het bovenbeen wordt 
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gehaald. Bij veel mitochondriële ziekten werken één of meerdere van deze complexen 
niet goed. Het meten van de enzymcomplexen is dan ook een belangrijk onderzoek, 
vooral als er getwijfeld wordt tussen een echte mitochondriële ziekte en een andere 
ziekte, die er qua klachten op lijkt. Eén van de ziektes die soms moeilijk te onderscheiden 
is van een mitochondriële ziekte is het chronisch vermoeidheidssyndroom (CVS). Zowel 
bij mitochondriële ziekten als bij CVS komen klachten van vermoeidheid en spierpijn 
na inspanning vaak voor. In hoofdstuk 2 hebben we onderzocht of het doormeten van 
de mitochondriële enzymcomplexen in een stukje spier gebruikt kan worden om mito-
chondriële ziekten te onderscheiden van CVS. Deze studie liet zien, dat bij patiënten met 
mitochondriële ziekten de enzymcomplexen inderdaad slechter werken dan bij patiënten 
met CVS. Ook hebben we de enzymcomplexen tussen CVS patiënten en gezonde proef-
personen vergeleken. Hiertussen waren geen verschillen. Wel bleken de spieren van CVS 
patiënten veel minder mitochondriën te bevatten dan die van gezonde proefpersonen.
Het onderzoek toont dus aan dat het meten van de mitochondriële enzymcomplexen 
bijdraagt aan het stellen van de diagnose van een mitochondriële ziekte. Verder blijken 
CVS patiënten op zich goed functionerende mitochondriën te hebben, maar hebben ze er 
wel minder dan gezonde personen. Het is niet helemaal duidelijk of de lagere hoeveel-
heid mitochondriën de oorzaak van CVS is, of het gevolg van verminderde lichamelijke 
activiteit.
Door het meten van de mitochondriële enzymcomplexen is dus het mogelijk een mito-
chondriële ziekte meer of minder waarschijnlijk te maken, maar het meest definitieve 
bewijs is het aantonen van een mutatie in het mitochondriële DNA. Er zijn verschillende 
mutaties in het mitochondrieël DNA die CPEO kunnen veroorzaken. In hoofdstuk 3 be-
schrijven we een patiënt met een mutatie die nog nooit eerder gevonden was bij CPEO.
KlachTen en aangeDane organen BIj cPeo
In hoofdstuk 4 hebben we de belangrijkste klachten in een groep van 28 CPEO patiënten 
in kaart gebracht. Het bleek dat zij vooral last hadden van vermoeidheid, pijn, depressie 
en beperkingen in de zelfredzaamheid. Om de ernst van deze klachten precies in te 
schatten hebben we de resultaten van deze groep CPEO patiënten vergeleken met een 
voor neurologen bekendere spierziekte, myotone dystrofie. Myotone dystrofie tast net als 
CPEO ook de spieren rondom de ogen en het hart aan en wordt over het algemeen gezien 
als een ernstige aandoening. Het bleek dat alle bovengenoemde klachten bij CPEO vaker 
voorkwamen en erger waren dan bij myotone dystrofie. Conclusie van deze studie is, dat 
CPEO een ernstige ziekte is, waarbij patiënten vaak meer klachten hebben dan je op het 
eerste oog zou verwachten.
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In hoofdstuk 5 hebben we onderzocht of CPEO patiënten problemen hebben met slapen. 
Slaapproblemen komen vaak voor bij patiënten met spierziekten en kunnen veel klachten 
geven in het functioneren overdag. We hebben 20 CPEO patiënten vragenlijsten over 
slapen voorgelegd. Driekwart vond dat zij slecht sliepen. Rusteloze benen en slaperig-
heid overdag waren andere veel voorkomende klachten. Alle deelnemers hebben ook een 
nacht geslapen aan een “slaapmonitor”. Hieruit bleek dat schoppende benen opvallend 
vaak voorkwamen. Enkele patiënten hadden ’s nachts opvallend lange adempauzes. Deze 
slaapproblemen zijn doorgaans goed te behandelen, waardoor de kwaliteit van leven aan-
zienlijk kan verbeteren. Of deze behandelingen net zo effectief zijn bij CPEO patiënten 
als bij verder gezonde personen, moet nog verder onderzocht worden.
In hoofdstuk 6 hebben we gekeken of de longen ook zijn aangedaan bij CPEO. Hiervoor 
hebben we bij 23 patiënten longfunctieonderzoek gedaan. CPEO bleek geen invloed 
te hebben op de longen zelf. Wel vonden we dat de spieren, die zorgen voor in- en 
uitademen vaak zwak waren, vooral bij patiënten die ook zwakte van de bovenarmen 
en –benen hadden. Zwakte van de ademhalingsspieren kan belangrijk zijn, aangezien dit 
ook kan leiden tot minder krachtig hoesten. Minder krachtig hoesten kan weer leiden tot 
longontstekingen, wat een belangrijke doodsoorzaak is onder CPEO patiënten. Het lijkt 
dus belangrijk om bij CPEO patiënten regelmatig de kracht van de ademhalingsspieren te 
controleren.
In hoofdstuk 7 hebben we onderzocht hoe vaak de nieren zijn aangetast bij CPEO. Bij 
andere mitochondriële ziekten komen nierfunctiestoornissen namelijk vaak voor. In onze 
studie was de nierfunctie bij alle 24 deelnemende CPEO patiënten normaal. Wel kwamen 
hoge bloeddruk en suikerziekte opvallend vaak voor. Ook bleek meer dan de helft van 
de patiënten last te hebben van incontintentie. De precieze oorzaak van incontinentie bij 
CPEO is onduidelijk. Dit moet nog verder onderzocht worden.
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Zorg voor patiënten met een mitochondriële ziekte is bij uitstek een multidisciplinaire 
aangelegenheid. Ook een proefschrift over mitochondriële ziekten schrijf je niet alleen. 
Vele personen hebben direct of indirect bijgedragen aan de totstandkoming hiervan. In dit 
dankwoord beperkt ik me tot enkele personen in het bijzonder.
Allereerst natuurlijk de patiënten, die ondanks hun ziekte toch altijd bereid waren bij te 
dragen aan de totstandkoming van dit proefschrift. Ik hoop dat dit proefschrift eraan zal 
bijdragen dat CPEO in de toekomst beter behandeld kan worden.
Beste Baziel (als AGNIO mocht ik je al geen prof. van Engelen meer noemen). Het is jouw 
opvatting dat promoveren meer is dan alleen het schrijven van een proefschrift. Promove-
ren is ook een persoonlijke ontwikkeling, een jeugdzonde. Ik waardeer het enorm dat je 
me veel vrijheid hebt gegeven om er mijn “eigen” boekje van te maken en me geduldig 
de kans hebt gegeven mijn eigen fouten te maken, zodat ik er nog meer van kon leren. 
Ik zal onze overlegmomenten missen, die net zo vaak niet als wel over mitochondriële 
zaken gingen.
Best Bert. Met je enorme moleculair-genetische kennis van mitochondriële ziekten bekeek 
je onze artikelen van een andere invalshoek, wat de kwaliteit altijd ten goede kwam. Ook 
heb je het publiceren van onze artikelen veel makkelijker gemaakt door de hele populatie 
genetisch in kaart te brengen. Bovendien, jij maakt het Brabants trio compleet, waardoor 
elk overleg vanzelfsprekend gemoedelijk en gezellig werd.
Het grootste deel van dit proefschrift gaat helemaal niet over neurologie. Zonder de kennis 
en het engelengeduld, waarmee Richard Rodenburg, Gijs Bleijenberg, Sebastiaan Over-
eem, Yvonne Heijdra en Jack Wetzels me wegwijs hebben gemaakt in hun vakgebied, zou 
er weinig van dit proefschrift terecht zijn gekomen. Vanzelfsprekend wil ik ook de andere 
medeauteurs bedanken voor hun aandeel in dit proefschrift.
Dank aan Femke Cuppen, longfunctielaborante, en aan de studenten die met hun 
wetenschappelijke stages hebben bijgedragen aan dit proefschrift: Marnix Kuindersma, 
Cathérine Delnooz en Henk-Jan Westeneng. Jullie hebben samen heel wat kilometers 
gemaakt om bij patiënten thuis metingen te verrichten. En natuurlijk aan ook Jiske Fer-
mont, ongetwijfeld de meest getalenteerde AIOS neurologie aller tijden. Je was namelijk 
al afgestudeerd neuroloog, nog voordat je wetenschappelijke stage van de doctoraalfase 
geneeskunde (hoofdstuk 4) gepubliceerd was.
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Alle collega’s met wie ik de onderzoekerskamer heb gedeeld wil ik bedanken voor de 
gezelligheid en voor het aanhoren van mijn onuitputtelijke gezeur over….. nou, over 
vanalles eigenlijk. Ook wil ik me excuseren voor mijn beperkte aandachtsspanne, waar-
door ik jullie zo vaak van het werk gehouden heb. 
Mijn neef Leon van Loon. Na ons eerste gesprek over het ontwerp van de kaft had ik eerlijk 
gezegd helemaal geen vertrouwen in een goede afloop, maar ik was meteen verkocht toen 
ik je ontwerp zag. Dè ge bedankt bènt, dè witte.
Mijn Maasstadse collega, Ritu Saxena, voor het vertalen van mijn steenkolen-engels naar 
keurig Oxford English. 
Dank aan de leden van manuscriptcommissie, prof. J. Smeitink, prof. S. Geurts en dr. R. 
de Coo, voor hun kritische en snelle beoordeling van het manuscript.
Mijn paranimfen, Bram en Willem,
Bram, in het licht van de arbeidsproductiviteit was het een kapitale fout van onze oplei-
ders om ons tijdens onze eerste onderzoekstage samen met mede-musketier Ruben op één 
kamer te plaatsen. Ik vond dit desalniettemin een erg leuke en leerzame tijd, waaruit ik 
enkele essentiële vaardigheden voor de rest van mijn leven meeneem. Hierbij denk ik niet 
alleen aan kennis van methodologie en statistiek, maar ook aan de diverese technieken 
voor het torpederen van een stapel plastic bekertjes met een elastiekje. Willem, jij hebt 
een zeer grote bijdrage aan de totstandkoming van dit proefschrift geleverd. Geen idee 
waar ik het over heb? Een hint: het was in Nürnberg en het had iets maken met een 
slaapgedepriveerde Bart, een aanstormende bus en een perfect getimede ruk aan de kraag 
van mijn jas.
Mijn schoonfamilie, Maria, Pim, Mijke en Remco,
Bedankt voor jullie interesse, voor de ontspanning tijdens diverse vakanties, en voor de 
hulp, als weer eens bleek dat een gezin bestaande uit twee promoverende artsen en twee 
jonge kinderen toch wel erg druk kan zijn.
Mijn broers, Edwin, Sander en Peter,
Edwin, als je op de lagere school zit, is een oudere broer die geneeskunde studeert echt 
heel stoer. Jij hebt me dan ook geïnspireerd om arts te worden. Ik ben blij dat je dat 
gedaan hebt, want het is echt een schitterend beroep. Sander, nadat jij gepromoveerd was, 
kon ik natuurlijk niet achterblijven. Het resultaat heb je nu voor je. Je hebt me in het begin 
ook enorm geholpen met tips voor “database-management”. De rest van de promotie 
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werd daardoor eigenlijk gewoon een kwestie van een paar drukken op de knop. Peter, 
bedankt voor je relativerende kijk op de zaken.
Mijn ouders,
Zonder jullie steun was er nooit een proefschrift gekomen. Jullie vonden een goede oplei-
ding altijd erg belangrijk. Als scholier of als student is dit belang niet altijd even duidelijk. 
Op die momenten wisten jullie me altijd weer te motiveren, altijd ondersteunend en nooit 
dwingend. Als je op de universiteit eenmaal weet wat ze van je verwachten, dan wordt 
afstuderen een trucje. Drie zonen op de universiteit laten afstuderen is daarentegen een 
prestatie van formaat. 
Lonneke, Tom en Sofie,
Lonneke, meestal wordt hier tegen de partner gezegd, dat het hele proefschift zonder hem 
of haar niet mogelijk was geweest. Ik geef toe dat jouw motivatie en werklust zeker een 
voorbeeld voor mij waren, maar het zijn toch vooral de ijsjes in de “Kruidtuin”, het racen 
over een Boliviaanse zoutvlakte, de helikoptervlucht over de Himalaya en natuurlijk onze 
geweldige kindjes, die zonder jou niet mogelijk waren geweest. Heel veel dank hiervoor.
Tom en Sofie, jullie zijn echt heerlijke kinderen, daar hoeft je niet voor gepromoveerd te 
zijn om dat te zien.
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Bart Smits is geboren op 14 mei 1976 in Deurne. In 1994 behaalde hij zijn VWO di-
ploma aan het Sint Willibrord gymnasium te Deurne. In hetzelfde jaar begon hij aan de 
geneeskundeopleiding aan de Katholieke Universiteit Leuven, België, om in 1995 over te 
stappen naar de geneeskundeopleiding aan de Katholieke Universiteit Nijmegen. Tijdens 
deze studie deed hij wetenschappelijk onderzoek naar de immuundeficiëntie agamma-
globulinemie (o.l.v. prof. J. van der Meer) en later in het kader van zijn wetenschappelijke 
stage naar de invloed van aangeboren stressgevoeligheid op vaattonusregulatie (o.l.v. 
prof. P. Smits). In 2001 behaalde hij zijn artsexamen en in 2002 begon hij bij de afdeling 
Neurologie in het UMC St. Radboud te Nijmegen, aanvankelijk als assistent geneeskunde 
niet in opleiding en later dat jaar als assistent geneeskunde in opleiding (opleider prof. 
G. Padberg). In 2003 startte hij onder leiding van prof. B. van Engelen en prof. L. van 
den Heuvel het onderzoek wat resulteerde in dit proefschrift. Na het voltooien van zijn 
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